Modified spacer oligomers and methods of use thereof
By designing antisense oligonucleotides containing modified nucleotides and locked nucleotides, the problems of nuclease degradation and hepatotoxicity of antisense oligonucleotides in the prior art in HBV treatment are solved, and the HBsAg is achieved Effectively reduce and improve liver safety.
Patent Information
- Application Number
- CN202380034549.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-03-17
- Filing Date
- 2023-03-16
- Publication Date
- 2024-11-26
AI Technical Summary
The existing antisense oligonucleotides in the treatment of HBV have problems with nuclease degradation and hepatotoxicity, and it is difficult to effectively reduce the level of HBsAg.
Develop antisense oligonucleotides (ASOs) containing 14-22 nucleotide units, with the central region at least 80% complementary to the target RNA sequence, including modified nucleotides such as N-tert-butyl-guanidine, N methyl -LNA and 5(Me)-propynyl, and contain 5' and 3' wing regions of locked nucleotides or 2' substituted nucleosides, enhance resistance and improve liver safety.
It improves the specificity and stability of antisense oligonucleotides on HBV targets, reduces the level of HBsAg, reduces the toxic effect on the liver, and provides a safer treatment plan.
Smart Images

Figure CN119032175A_ABST
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims priority under 35 U.S.C. §119 to provisional application serial number 63 / 321,019, filed on March 17, 2022, the disclosure of which is incorporated herein by reference. Background Art
[0003] The following discussion is provided to assist the reader in understanding the present disclosure, and is not admitted to describe or constitute prior art thereof.
[0004] Approximately 300 million people worldwide are chronically infected with HBV. HBsAg loss is a key aspect of "functional cure" and is the goal of many new therapeutics. Antisense oligonucleotides have been shown to be an effective way to reduce HBsAg in animal models, and clinical studies of these molecules are ongoing.
[0005] However, the use of antisense oligonucleotides to treat HBV still has problems such as nuclease degradation and liver toxicity. Therefore, there is a need in the art to discover antisense oligonucleotides that have greater resistance to nuclease degradation and improved liver safety properties. Summary of the invention
[0006] The present disclosure relates to compounds and compositions containing oligonucleotides and their use in preventing or treating diseases and disorders such as hepatitis B (HBV).
[0007] In one aspect, the present disclosure provides an antisense oligonucleotide (ASO) comprising 14-22 nucleotide units, and:
[0008] (a) a central region (B') comprising 6 or more consecutive DNA nucleotides;
[0009] (b) a 5' wing (A') comprising 2 to 6 locked nucleotides or 2' substituted nucleosides; and
[0010] (c) a 3' wing (C') comprising 2 to 6 locked nucleotides or 2' substituted nucleosides;
[0011] wherein the central region of the ASO is at least 80% complementary or hybridizes to the target RNA sequence; and wherein the ASO comprises at least one modified nucleotide selected from:
[0012] (N-tert-butyl-guanidine (Gutb)), wherein B is a nucleobase,
[0013] (N-methyl-LNA(Nmln)), wherein B is a nucleobase,
[0014] (G-clamp), and
[0015] (5(Me)-propynyl(5prnl)).
[0016] In another aspect, the present disclosure provides an antisense oligonucleotide (ASO) comprising 14-22 nucleotide units, and: (a) a central region (B') comprising 6 or more consecutive DNA nucleotides, wherein at least one of the consecutive DNA nucleotides is a modified nucleotide selected from Gutb, Nmln, G-clamp and 5prnl;
[0017] (b) a 5' wing (A') comprising 2 to 6 locked nucleotides or 2' substituted nucleosides; and
[0018] (c) a 3' wing (C') comprising 2 to 6 locked nucleotides or 2' substituted nucleosides;
[0019] The central region of the ASO is at least 80% complementary or hybridizing to the target RNA sequence.
[0020] In another aspect, the present disclosure provides an antisense oligonucleotide (ASO) comprising 14-22 nucleotide units, and: (a) a central region (B') comprising 6 or more consecutive DNA nucleotides; (b) a 5' wing region (A') comprising 2 to 6 locked nucleotides or 2' substituted nucleosides; and (c) a 3' wing region (C') comprising 2 to 6 locked nucleotides or 2' substituted nucleosides; wherein the central region of the ASO is at least 80% complementary or hybridized to a target RNA sequence; and wherein (i) the central region (B') comprises a modified nucleotide selected from G-clamp and 5prnl, (ii) the 5' wing region (A') comprises a modified nucleotide selected from Gutb and Nmln, (iii) the 3' wing region (C') comprises a modified nucleotide selected from Gutb and Nmln, or (iv) any combination thereof.
[0021] In some embodiments, the central region (B') comprises 2, 3, 4, 5, or 6 or more modified nucleotides.
[0022] In some embodiments, the 5' wing (A'), the 3' wing (C'), or both comprise a modified nucleotide selected from Gutb, Nmln, G-clamp, and 5prnl.
[0023] In some embodiments, the ASO molecule further comprises one or more phosphorothioate (ps) internucleoside linkages, methylsulfonylphosphoramidate (yp) internucleoside linkages, or a combination thereof.
[0024] In some embodiments, the ASO molecule further comprises at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, or 22 phosphorothioate (ps) internucleoside linkages, methylsulfonylphosphoramidate (yp) internucleoside linkages, or a combination thereof.
[0025] In another aspect, the present disclosure provides an antisense oligonucleotide (ASO) comprising 14-22 nucleotide units, wherein the ASO comprises:
[0026] (a) a central region (B') comprising 6 or more consecutive DNA nucleotides, wherein at least one of the consecutive DNA nucleotides is a modified nucleotide,
[0027] (b) a 5' wing (A') comprising 2 to 6 locked nucleotides or 2' substituted nucleosides, and
[0028] (c) a 3' wing (C') comprising 2 to 6 locked nucleotides or 2' substituted nucleosides,
[0029] wherein the central region of the ASO is at least 80% complementary or hybridizes to a target RNA sequence, and wherein the ASO comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or more methylsulfonylphosphoramidate (yp) internucleoside linkages.
[0030] In some embodiments, the ASO comprises at least 1, at least 2, at least 3, at least 4, or at least 5 or more nucleotides selected from:
[0031] (N-tert-butyl-guanidine (Gutb)), wherein B is a nucleobase,
[0032] (N-methyl-LNA(Nmln)), wherein B is a nucleobase,
[0033] (G-clamp), and
[0034] (5(Me)-propynyl(5prnl)).
[0035] In some embodiments, the ASO molecule further comprises one or more phosphorothioate (ps) internucleoside bonds.
[0036] In some embodiments of any of the aforementioned aspects, (i) at least one methylsulfonyl phosphoramidate (yp) internucleotide bond is located between nucleoside positions 3 and 4 from the 5' end of the ASO molecule; (ii) at least one methylsulfonyl phosphoramidate (yp) internucleotide bond is located between nucleoside positions 5 and 6 from the 5' end of the ASO molecule; (iii) at least one methylsulfonyl phosphoramidate (yp) internucleotide bond is located between nucleoside positions 6 and 7 from the 5' end of the ASO molecule; (iv) at least one methylsulfonyl phosphoramidate (yp) internucleotide bond is located between nucleoside positions 7 and 8 from the 5' end of the ASO molecule; (v) at least one methylsulfonyl phosphoramidate (yp) internucleotide bond is located between nucleoside positions 8 and 9 from the 5' end of the ASO molecule; (vi) at least one methylsulfonyl phosphoramidate (yp) internucleotide bond is located between nucleoside positions 9 and 10 from the 5' end of the ASO molecule; or (vii) a combination thereof.
[0037] In some embodiments of any of the aforementioned aspects, the 5' wing (A'), the 3' wing (C'), or both comprise at least one methylsulfonylphosphoramidate (yp) internucleotide linkage.
[0038] In some embodiments of any of the foregoing aspects, the ASO molecule further comprises galactosamine. In some embodiments, the galactosamine is N-acetylgalactosamine (GalNAc) of formula (VI):
[0039]
[0040] ,in
[0041] m is 1, 2, 3, 4 or 5;
[0042] Each n is independently 1 or 2;
[0043] p is 0 or 1;
[0044] Each R is independently H;
[0045] each Y is independently selected from —OP(═O)(SH)—, —OP(═O)(O)—, —OP(═O)(OH)—, and —OP(S)S—;
[0046] Z is H or a second protecting group;
[0047] L is a linker or L and Y in combination are a linker; and
[0048] A is H, OH, a third protecting group, an activating group or an oligonucleotide.
[0049] In some embodiments, the galactosamine is N-acetylgalactosamine (GalNAc) of formula (VII):
[0050]
[0051] Where R z is OH or SH; and each n is independently 1 or 2.
[0052] In some embodiments of any of the foregoing aspects, (i) the target RNA sequence is a viral gene; (ii) the target RNA sequence is a gene from a DNA virus; (iii) the target RNA sequence is a gene from a double-stranded DNA (dsDNA) virus; (iv) the target RNA sequence is a gene from a hepadnavirus; (v) the target RNA sequence is a gene from hepatitis B virus (HBV); (vi) the target RNA sequence is a gene from HBV of any one of genotypes AJ; or (vii) the target RNA sequence is selected from the S gene or X gene of HBV.
[0053] In some embodiments of any of the foregoing aspects, the target RNA sequence is selected from a gene encoding a methylation-controlled J protein (MCJ protein), a gene encoding TAZ, a gene encoding angiopoietin-like 3 (ANGPTL3), a gene encoding diacylglycerol acyltransferase 2 (DGAT2), and a gene encoding hydroxysteroid 17-β dehydrogenase 13 (HSD17B13).
[0054] In some embodiments of any of the foregoing aspects, wherein (i) the 5' wing of the ASO comprises 2 to 6 phosphorothioate-linked locked nucleosides, (ii) the 3' wing of the ASO comprises 2 to 6 phosphorothioate-linked locked nucleosides, or (iii) a combination thereof. In some embodiments, wherein the locked nucleosides are selected from LNA, ScpBNA, AmNA, AmNA(N-Me), GuNA, GuNA(NR 11 ), where R 11 Selected from Me, Et, i-Pr, t-Bu and combinations thereof.
[0055] In some embodiments of any of the aforementioned aspects, the central region of the ASO comprises at least 5 consecutive phosphorothioate-linked DNA nucleotides, at least 5 consecutive methylsulfonylphosphoramidate-linked DNA nucleotides, or at least 5 consecutive DNA nucleotides linked by one or more phosphorothioate internucleoside bonds and one or more methylsulfonylphosphoramidate internucleoside bonds.
[0056] In some embodiments of any of the foregoing aspects, the central region of the ASO comprises 8 to 10 consecutive phosphorothioate-linked DNA nucleotides, 8 to 10 consecutive methylsulfonylphosphoramidate-linked DNA nucleotides, or 8 to 10 DNA nucleotides linked by one or more phosphorothioate internucleoside bonds and one or more methylsulfonylphosphoramidate internucleoside bonds.
[0057] In some embodiments of any of the aforementioned aspects, the ASO comprises at least one modified nucleotide having the structure
[0058] (“(2s)T”), (“(5OH)C”), (“(8nh)A”), ("(8nh)G") or
[0059] in:
[0060] R is halogen or R'-C≡C-; and
[0061] R' is C 6-12 Aryl, 5- to 12-membered heteroaryl, hydroxy-C 1-6 Alkyl or C 1-7 Alkanoyloxy.
[0062] In some embodiments of any of the aforementioned aspects, the ASO comprises at least one modified nucleotide having the structure:
[0063]
[0064] in:
[0065] W is independently O, N or S;
[0066] R1, R2 and R5 are independently H or D;
[0067] R3 is H or F;
[0068] R4 is F or OCH3; and
[0069] Base is
[0070]
[0071]
[0072] in:
[0073] R is halogen or R'-C≡C-; and
[0074] R' for C 6-12Aryl, 5- to 12-membered heteroaryl, hydroxyl C 1-6 Alkyl or C 1-7 Alkanoyloxy.
[0075] In another aspect, the present disclosure provides ASO molecules as shown in Table 1.
[0076] In another aspect, the disclosure provides a pharmaceutical composition comprising an ASO molecule disclosed herein (eg, any one of the aforementioned aspects or embodiments); and a pharmaceutically acceptable excipient.
[0077] In some embodiments, the pharmaceutical composition may further comprise 2, 3, 4, 5, 6, 7, 8, 9, 10 or more ASO molecules disclosed herein.
[0078] In some embodiments, the pharmaceutical composition may further comprise an additional therapeutic agent. In some embodiments, the additional therapeutic agent is selected from nucleotide analogs, nucleoside analogs, capsid assembly regulators (CAMs), recombinant interferons, entry inhibitors, small molecule immunomodulators, and oligonucleotide therapies, wherein the oligonucleotide therapies are optionally selected from additional antisense oligonucleotides (ASOs), short interfering nucleic acids (siNAs), NAPs, or STOPS TM .
[0079] In another aspect, the present disclosure provides a method of treating a subject having hepatitis B virus (HBV) infection, the method comprising administering to the subject having HBV an ASO or pharmaceutical composition disclosed herein (eg, any of the preceding aspects or embodiments).
[0080] In some embodiments, the method may further comprise administering an additional therapeutic agent. In some embodiments, the additional therapeutic agent is selected from nucleotide analogs, nucleoside analogs, capsid assembly regulators (CAMs), recombinant interferons, entry inhibitors, small molecule immunomodulators, and oligonucleotide therapies, wherein the oligonucleotide therapies are optionally selected from additional antisense oligonucleotides (ASOs), short interfering nucleic acids (siNAs), NAPs, or STOPS TMIn some embodiments, the additional therapeutic agent is selected from the group consisting of ALG-010133, ALG-000184, recombinant interferon α2b, IFN-a, PEG-IFN-a-2a, lamivudine, telbivudine, adefovir dipivoxil, clavudine, entecavir, tenofovir alafenamide, tenofovir disoproxil, NVR3-778, BAY41-4109, JNJ-632, JNJ-3989 ( In some embodiments, the ASO and the additional therapeutic agent are administered simultaneously or sequentially.
[0081] In some embodiments, treating comprises reducing HBV viral load in a subject, reducing viral antigen levels in a subject, or a combination thereof.
[0082] On the other hand, the present disclosure provides a method for reducing the expression of a target gene in a subject, the method comprising administering to the subject an ASO or a pharmaceutical composition disclosed herein. In some embodiments, the target gene is an endogenous gene for the subject or the target gene is not endogenous to the subject. In some embodiments, the subject suffers from a disease selected from hepatitis B virus (HBV), coronavirus infection and liver disease, wherein the liver disease is optionally selected from non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC).
[0083] In some embodiments of the disclosed methods, the subject is a mammal, optionally an adult human.
[0084] In some embodiments of the disclosed methods, the ASO is administered at a dose of at least 1 mg / kg, 2 mg / kg, 3 mg / kg, 4 mg / kg, 5 mg / kg, 6 mg / kg, 7 mg / kg, 8 mg / kg, 9 mg / kg, 10 mg / kg, 11 mg / kg, 12 mg / kg, 13 mg / kg, 14 mg / kg, or 15 mg / kg.
[0085] In some embodiments of the disclosed methods, the ASO is administered at 0.5 mg / kg to 50 mg / kg, 0.5 mg / kg to 40 mg / kg, 0.5 mg / kg to 30 mg / kg, 1 mg / kg to 50 mg / kg, 1 mg / kg to 40 mg / kg, 1 mg / kg to 30 mg / kg, 1 mg / kg to 20 mg / kg, 3 mg / kg to 50 mg / kg, 3 mg / kg to 40 mg / kg, 3 mg / kg to 30 mg / kg, 3 mg / kg to 20 mg / kg, 3 mg / kg to 15 mg / kg. , 3mg / kg to 10mg / kg, 4mg / kg to 50mg / kg, 4mg / kg to 40mg / kg, 4mg / kg to 30mg / kg, 4mg / kg to 20mg / kg, 4mg / kg to 15mg / kg, 4mg / kg to 10mg / kg, 5mg / kg to 50mg / kg, 5mg / kg to 40mg / kg, 5mg / kg to 30mg / kg, 5mg / kg to 20mg / kg, 5mg / kg to 15mg / kg, or 5mg / kg to 10mg / kg.
[0086] In some embodiments of the disclosed methods, the ASO is administered at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 times.
[0087] In some embodiments of the disclosed methods, the ASO is administered at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 times a day, at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 times a week, or at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 times a month.
[0088] In some embodiments of the disclosed methods, the ASO is administered at least once every 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or 21 days.
[0089] In some embodiments of the disclosed methods, the ASO is administered for a period of at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or 21 days, or for a period of at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 51, 52, 53, 54, or 55 weeks.
[0090] The foregoing general description and the following detailed description are exemplary and illustrative, and are intended to provide further explanation of the disclosure claimed. Other objects, advantages and novel features will be apparent to those skilled in the art from the following brief description of the drawings and the detailed description of the disclosure. BRIEF DESCRIPTION OF THE DRAWINGS
[0091] The Fig shows the improvement in in vivo efficacy of the selected ASOs relative to the LNA-DNA-LNA parent. G01 is vehicle, dosed SC at 5 mL / kg; G02 is ASO 59, dosed SC once on day 0 at 5 mg / kg; G-04 is ASO 84, dosed SC once on day 0 at 5 mg / kg. DETAILED DESCRIPTION
[0092] The present disclosure relates to modified antisense oligonucleotides and pharmaceutical compositions of modified antisense oligonucleotides. The present disclosure also relates to methods of using and preparing antisense oligonucleotides and pharmaceutical compositions.
[0093] Antisense Oligonucleotides (ASOs)
[0094] The compounds disclosed herein include modified antisense oligonucleotides (ASOs). In some embodiments, the ASO comprises 14-22 nucleotide units, such as 14, 15, 16, 17, 18, 19, 20, 21 or 22 nucleotide units. In some embodiments, the ASO is a spacer comprising the following three regions: a 5' wing region (A') comprising modified nucleotides; a central region (B') comprising nucleotides of a different type from the wing (e.g., nucleotides capable of inducing RNase H cleavage); and a 3' wing region (C') comprising modified nucleotides.
[0095] The disclosed ASOs comprise (i) a modified nucleotide, such as Gutb, Nmln, 5prnl, G-clamp, or a combination thereof; (ii) at least one methylsulfonylphosphoramidate internucleoside bond (when R a When it is a methyl group, it is referred to as "yp" in the sequence); or (iii) a combination thereof. The structures of Gutb, Nmln, 5prnl and G-clamp are shown below, and the structure of the methylsulfonyl phosphoramidate linker is: Where R a C1-C6 alkyl, C 6-12 Aryl or 5- to 12-membered heteroaryl.
[0096] In some embodiments, the structure of the methylsulfonyl phosphoramidate linker is:
[0097]
[0098] For example, the 5' wing and the 3' wing can each independently comprise 2-6 nucleotides, such as 2, 3, 4, 5 or 6 nucleotides. One or more of these nucleotides can be modified (e.g., 1, 2, 3, 4, 5 or 6 nucleotides are modified). At least one of the modified nucleotides can comprise the following structure: (N-tert-butyl-guanidine (Gutb)) or (N-methyl-LNA(Nmln)), wherein B is a nucleobase. Additionally or alternatively, at least one of the modified nucleotides may comprise the following structure:
[0099] (G-clip) or (5(Me)-propynyl (5prnl)). Therefore, the 5' wing region and the 3' wing region can each independently comprise Gutb, Nmln, or one or more of the two. Similarly, the 5' wing region and the 3' wing region can each independently comprise G-clamp, 5prnl, or one or more of the two; however, G-clamp and 5prnl are also suitable for inclusion in the central region. For example, in some embodiments, (i) the central region (B') comprises a modified nucleotide selected from G-clamp and 5prnl, (ii) the 5' wing region (A') comprises a modified nucleotide selected from Gutb and Nmln, (iii) the 3' wing region (C') comprises a modified nucleotide selected from Gutb and Nmln, or (iv) any combination thereof.
[0100] Additionally or alternatively, the central region may include 1, 2, 3, 4, 5 or more continuous DNA nucleosides connected by phosphodiester internucleoside bonds or thiophosphate ("ps") internucleoside bonds. In other embodiments, the central region includes one or more modified nucleotides, methylsulfonyl phosphoramidate (yp) internucleoside bonds or combinations thereof. Further, the central region may include one or more modified nucleotides, wherein the central region can induce RNAse H cleavage. In certain embodiments, the central region includes one or more modified nucleotides with modified nucleobases. In certain embodiments, the central region includes 6, 7, 8, 9, 10 or 11 continuous DNA nucleosides. In certain embodiments, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11 DNA nucleosides of the DNA nucleosides in the central region are modified. At least one modified nucleotide in the modified nucleotide may include the following structure: (N-tert-butyl-guanidine (Gutb)) or (N-methyl-LNA(Nmln)),
[0101] Wherein B is a nucleobase. Additionally or alternatively, at least one of the modified nucleotides may comprise the following structure:
[0102] (G-clip) or (5(Me)-propynyl(5prnl)).
[0103] For the purposes of the present disclosure, the disclosed ASOs may comprise at least 1, at least 2, at least 3, at least 4, or at least 5 or more of Gutb, Nmln, 5prnl, G-clamps, or a combination thereof. Gutb, Nmln, 5prnl, G-clamps, or a combination thereof may be incorporated into the central region, the wing region, or both. In general, the modified locked nucleotides (Gutb and Nmln) are suitable for inclusion in the wing region, while 5prnl and G-clamps are suitable for inclusion in the entire ASO or specifically in the central region. Additionally or alternatively, the disclosed ASOs may comprise 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or more methylsulfonylphosphoramidate (yp) internucleoside bonds.
[0104] In some aspects, the spacer ASO compounds of the present disclosure include compounds of formula (I):
[0105] A'—B'—C',
[0106] Wherein A' and C' each independently comprise 2-6 nucleotides, one or more of which are modified nucleotides, and B' comprises 6 or more consecutive DNA nucleosides connected by phosphodiester or phosphorothioate internucleoside bonds. In certain embodiments, B' comprises one or more modified DNA nucleosides. In certain embodiments, the modified nucleotides are selected from locked nucleosides or 2' substituted nucleosides. In certain embodiments, the modified DNA nucleosides are selected from locked nucleosides or 2' substituted nucleosides.
[0107] The number of nucleotides and / or nucleosides in A', B' and C' can be selected from the following group (A':B':C'): (2:10:2), (2:10:3), (2:10:4), (2:10:5), (3:10:2), (3:10:3), (3:10:4), (3:10:5), (4:10:2), (4:10:3), (4:10:4), (4:10:5), (5:10:2), (5:10:3), (5:10:4), (5:10:5), (2:9:2), (2:9:3), (2:9:4), (2:9:5), (3:9:2), (3:9:3), (3:9:4), (3:9:5), (4:9:2), (4:9:3), (4:9:4), (4:9:5), (5:9:2), (5:9:3), (5:9:4), (5:9:5), (2:8:2), (2:8:3), (2:8:4), (2:8:5), (3:8: 2), (3:8:3), (3:8:4), (3:8:5), (4:8:2), (4:8:3), (4:8:4), (4:8:5), (5:8:2), (5:8:3), (5:8:4), (5:8:5), (2:7:2), (2:7:3), (2:7:4), (2:7:5), (3:7:2), (3:7:3), (3:7:4), (3:7:5), (4:7:2), (4:7:3), (4 :7:4), (4:7:5), (5:7:2), (5:7:3), (5:7:4), (5:7:5), (2:6:2), (2:6:3), (2:6:4), (2:6:5), (3:6:2), (3:6:3), (3:6:4), (3:6:5), (4:6:2), (4:6:3), (4:6:4), (4:6:5), (5:6:2), (5:6:3), (5:6:4), and (5:6:5).
[0108] In some embodiments, the 5' wing region comprises one or more locked nucleosides or 2' substituted nucleosides. In some embodiments, the 3' wing region comprises one or more locked nucleosides or 2' substituted nucleosides. In some embodiments, the central region comprises one or more locked nucleosides or 2' substituted nucleosides. In some embodiments, the 5' wing region, the 3' wing region, the central region or a combination thereof comprises one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15) locked nucleosides or 2' substituted nucleosides. The locked nucleosides may contain a bridge between the 4' and 2' positions of the sugar, wherein the bridge comprises 2 to 4 optional substituted atoms. For example, LNA nucleosides are:
[0109] Other exemplary locked nucleosides include the following:
[0110] (ScpBNA or “cp”); (AmNA, when R 10 When H; AmNA(N-Me), when R 10 When CH3; AmNA (N-alkyl), when R 10 is C1-C6 alkyl); (GuNA); or (GuNA(NR 11 ); wherein B is a nucleobase; R 10 is H or C1-C6 alkyl; and R 11 In certain embodiments, all nucleosides in the 5' wing region are locked nucleosides. In certain embodiments, all nucleosides in the 3' wing region are locked nucleosides. In certain embodiments, the 3' wing region comprises LNA and one or two nucleosides selected from ScpBNA, AmNA and GuNA. In certain embodiments, the 5' wing region is all LNA, and the 3' wing region contains LNA and one or two nucleosides selected from ScpBNA, AmNA and GuNA. Other nucleotides are included in PCT / JP2010 / 068409, PCT / JP2013 / 075370, PCT / JP2015 / 054308, PCT / JP2018 / 006061 and / or PCT / JP2018 / 006062, which are incorporated herein by reference in their entirety. Gutb and Nmln are other examples of locked nucleotides that may be included in the 5' wing region or the 3' wing region or both.
[0111] In certain embodiments, the 5' wing region of ASO comprises 2 to 6 locked nucleosides connected by thiophosphate, locked nucleosides connected by mesylphosphoramidate or their combination.In certain embodiments, the 5' wing region comprises 2 to 6 2' substituted nucleosides connected by thiophosphate, 2' substituted nucleosides connected by mesylphosphoramidate or their combination.In certain embodiments, the 5' wing region comprises at least one locked nucleoside and at least one 2' substituted nucleoside, wherein the locked nucleoside and the 2' substituted nucleoside are connected by thiophosphate joint or mesylphosphoramidate joint.In certain embodiments, the 5' wing region further comprises RNA nucleosides or DNA nucleosides, wherein RNA nucleosides and DNA nucleosides are not locked nucleosides or 2' substituted nucleosides.In certain embodiments, at least two nucleosides in the 5' wing region are connected by thiophosphate joint or mesylphosphoramidate joint.In certain embodiments, at least 2,3,4,5 or 6 nucleosides in the 5' wing region are connected by thiophosphate joint, mesylphosphoramidate joint or their combination.
[0112] In some embodiments, the 3' wing region of ASO comprises 2 to 6 locked nucleosides connected by thiophosphate, locked nucleosides connected by mesylphosphoramidate or their combinations. In some embodiments, the 3' wing region comprises 2 to 6 substituted nucleosides connected by thiophosphate, substituted nucleosides connected by mesylphosphoramidate or their combinations. In some embodiments, the 3' wing region comprises at least one locked nucleoside and at least one 2' substituted nucleoside, wherein the locked nucleoside and the 2' substituted nucleoside are connected by thiophosphate joints or mesylphosphoramidate joints. In some embodiments, the 3' wing region further comprises RNA nucleosides or DNA nucleosides, wherein RNA nucleosides and DNA nucleosides are not locked nucleosides or 2' substituted nucleosides. In some embodiments, at least two nucleosides in the 3' wing region are connected by thiophosphate joints or mesylphosphoramidate joints. In some embodiments, at least 2, 3, 4, 5 or 6 nucleosides in the 3' wing region are connected by thiophosphate joints, mesylphosphoramidate joints or their combinations.
[0113] In some embodiments, one or more nucleotides in the 5' wing and / or 3' wing comprise a phosphorothioate nucleoside bond or a methylsulfonyl phosphoramidate nucleoside bond. In some embodiments, all nucleotides in the 5' wing comprise a phosphorothioate nucleoside bond. In some embodiments, all nucleotides in the 3' wing comprise a phosphorothioate nucleoside bond. In some embodiments, all nucleotides in the 5' wing comprise a methylsulfonyl phosphoramidate nucleoside bond. In some embodiments, all nucleotides in the 3' wing comprise a methylsulfonyl phosphoramidate nucleoside bond.
[0114] In some embodiments, the central region comprises one or more modified nucleotides having modified nucleobases. For example, the central region may comprise at least 1, at least 2, at least 3, at least 4, or at least 5 or more of Gutb, Nmln, 5prnl, G-clamp, or a combination thereof. In some embodiments, the central region comprises at least 1, at least 2, at least 3, at least 4, or at least 5 or more of 5prnl, G-clamp, or a combination thereof. Additionally or alternatively, the central region may comprise one or more modified nucleotides having the following structure: (“(2s)T”), (“(5OH)C”), (“(8nh)A”, (“(8nh)G”) and / or Where R is halogen or R'-C≡C-; and R' is C 6-12 Aryl, 5- to 12-membered heteroaryl, hydroxy-C 1-6 Alkyl or C 1-7In some embodiments, the central region comprises a modified nucleotide (e.g., (2s)T or (5OH)C) at the 1st, 2nd, 3rd, or 4th interstitial nucleoside position (from the 5' end). In some embodiments, the modified nucleotide is at the 3rd interstitial nucleoside position (from the 5' end). In some embodiments, the modified nucleotide is a nucleotide having the following structure:
[0115]
[0116] in:
[0117] W is independently O, N or S;
[0118] R1, R2 and R5 are independently H or D;
[0119] R3 is H or F;
[0120] R4 is F or OCH3; and
[0121] Base is
[0122]
[0123]
[0124] in:
[0125] R is halogen or R'-C≡C-; and
[0126] R' for C 6-12 Aryl, 5- to 12-membered heteroaryl, hydroxyl C 1-6 Alkyl or C 1-7 In some embodiments, C 1-7 Alkanoyl includes but is not limited to formyl, acetyl, ethylcarbonyl, n-propylcarbonyl, isopropylcarbonyl, n-butylcarbonyl, isobutylcarbonyl, tert-butylcarbonyl, n-pentylcarbonyl and n-hexylcarbonyl. Other modified nucleotides include those in PCT / JP2018 / 006061, which are incorporated herein by reference in their entirety.
[0127] As used herein, unless otherwise indicated, "aryl" refers to a carbocyclic (all-carbon) ring with a completely delocalized π-electron system. An "aryl" group can be composed of two or more fused rings (rings that share two adjacent carbon atoms). When the aryl group is a fused ring system, the ring connected to the rest of the molecule has a completely delocalized π-electron system. The other rings in the fused ring system may or may not have a completely delocalized π-electron system. Examples of aryl groups include, but are not limited to, free radicals of benzene, naphthalene, and azulene.
[0128] As used herein, unless otherwise indicated, "heteroaryl" refers to a ring with a completely delocalized π electron system, and contains one or more heteroatoms (e.g., one to three heteroatoms, or one to four heteroatoms, or one to five heteroatoms) independently selected from the group consisting of nitrogen, oxygen and sulfur in the ring. A "heteroaryl" group can be composed of two or more fused rings (rings sharing two adjacent carbon atoms). When the heteroaryl is a fused ring system, the ring connected to the rest of the molecule has a completely delocalized π electron system. Other rings in the fused ring system may or may not have a completely delocalized π electron system. Examples of heteroaryl rings include, but are not limited to, furan, thiophene, pyrrole, oxazole, thiazole, imidazole, pyrazole, isoxazole, isothiazole, triazole, thiadiazole, pyridine, pyridazine, pyrimidine, pyrazine and triazine.
[0129] In certain embodiments, the central region of ASO comprises at least 5 continuous DNA nucleosides connected by phosphorothioates, at least 5 continuous DNA nucleosides connected by mesylphosphoramidates or their combination. In certain embodiments, at least 2,3,4,5 or 6 nucleosides in the central region are connected by phosphorothioate joints, mesylphosphoramidate joints or their combination. In certain embodiments, the DNA nucleosides in the central region are connected to the nucleosides in the 5' wing region by phosphorothioate joints or mesylphosphoramidate joints. In certain embodiments, the DNA nucleosides in the central region are connected to the nucleosides in the 3' wing region by phosphorothioate joints or mesylphosphoramidate joints. In certain embodiments, the central region comprises 8 to 10 continuous DNA nucleosides connected by phosphorothioates, 8-10 continuous DNA nucleosides connected by mesylphosphoramidates or their combination.
[0130] In some embodiments, the ASO is complementary or hybridized to a viral target RNA sequence starting in the X region of HBV or the S region of HBV. For example, an important target can start at the 5' end of the target site in acc.KC315400.1 (genotype B, "gt B"), or any of genotypes A, C or D. The skilled person will understand the HBV position, for example, as described in Wing-Kin Sung et al., Nature Genetics 44:765 (2012). In some embodiments, the S region is defined as from the beginning of the small S protein (in genotype B KC315400.1 isolate, position #155) to the beginning of the X protein (in genotype B KC315400.1 isolate, position #1373) before. In some embodiments, the X region is defined as from the beginning of the X protein (in genotype B KC315400.1 isolate, position #1374) to the end of the DR2 locus (in genotype B KC315400.1 isolate, position #1603).
[0131] In some embodiments, the ASO is complementary to or hybridizes to a viral target RNA sequence comprising or consisting essentially of at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 contiguous nucleotides within positions 100-800 or 1050-1700 of SEQ ID NO: 89. In some embodiments, the ASO is complementary to or hybridizes to a viral target RNA sequence comprising or consisting essentially of 5 to 15, 5 to 14, 5 to 13, 5 to 12, 5 to 11, 5 to 10, 5 to 9, 5 to 8, 6 to 15, 6 to 14, 6 to 13, 6 to 12, 6 to 11, 6 to 10, 7 to 15, 7 to 14, 7 to 13, 7 to 12, or 7 to 11 contiguous nucleotides within positions 100-800 or 1050-1700 of SEQ ID NO: 89. In some embodiments, the ASO is complementary to or hybridizes to a viral target RNA sequence comprising, consisting of, or consisting essentially of, at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 contiguous nucleotides within positions 180-280, 300 to 450, 650 to 775, 1125 to 1300, or 1400 to 1650 of SEQ ID NO:89. In some embodiments, the ASO is complementary to or hybridizes to a viral target RNA sequence comprising or consisting essentially of at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 contiguous nucleotides within positions 180 to 215, 230 to 270, 350 to 420, 675 to 730, 1165 to 1210, 1245 to 1290, 1400 to 1480, or 1500 to 1630 of SEQ ID NO: 89. In some embodiments, the ASO is complementary to or hybridizes to a viral target RNA sequence comprising or consisting essentially of at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 contiguous nucleotides within positions 180 to 215, 230 to 270, 350 to 420, 675 to 730, 1165 to 1210, 1245 to 1290, 1400 to 1480, or 1500 to 1630 of SEQ ID NO: 89. NO: 89, starting at position 191, 245, 246, 276, 376, 377, 381, 383, 694, 700, 1182, 1261, 1262, 1408, 1410, 1426, 1431, 1432, 1433, 1435, 1438, 1441, 1443, 1513, 1516, 1517, 1518, 1519, 1520, 1521, 1522, 1527, 1559, 1575, 1576, 1577, 1580, 1581, 1582, or 1589 of consecutive nucleotides. In some embodiments, the ASO is fully complementary to the viral target RNA sequence. In some embodiments, there are less than or equal to 5, 4, 3, 2, or 1 mismatch between the ASO and the viral target sequence.In some embodiments, there are less than or equal to 2 mismatches between the ASO and the viral target sequence. In some embodiments, there are less than or equal to 1 mismatch between the ASO and the viral target sequence. In some embodiments, the mismatch is located in the wing region of the ASO. In some embodiments, the mismatch is located in the 5' wing region of the ASO. In some embodiments, the mismatch is located in the 3' wing region of the ASO. In some embodiments, the mismatch is located in the central region of the ASO.
[0132] In some embodiments, the central region is complementary to or hybridizes to a viral target RNA sequence comprising or consisting essentially of at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 contiguous nucleotides located within positions 100-800 or 1050-1700 of SEQ ID NO: 89. In some embodiments, the central region is complementary to or hybridizes to a viral target RNA sequence comprising or consisting essentially of 5 to 15, 5 to 14, 5 to 13, 5 to 12, 5 to 11, 5 to 10, 5 to 9, 5 to 8, 6 to 15, 6 to 14, 6 to 13, 6 to 12, 6 to 11, 6 to 10, 7 to 15, 7 to 14, 7 to 13, 7 to 12, or 7 to 11 contiguous nucleotides located within positions 100-800 or 1050-1700 of SEQ ID NO: 89. In some embodiments, the central region is complementary to or hybridizes to a viral target RNA sequence comprising or consisting essentially of at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 contiguous nucleotides located within positions 180-280, 300 to 450, 650 to 775, 1125 to 1300, or 1400 to 1650 of SEQ ID NO:89. In some embodiments, the central region is complementary to or hybridizes to a viral target RNA sequence comprising or consisting essentially of at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 contiguous nucleotides located within positions 180 to 215, 230 to 270, 350 to 420, 675 to 730, 1165 to 1210, 1245 to 1290, 1400 to 1480, or 1500 to 1630 of SEQ ID NO: 89. In some embodiments, the central region is complementary to or hybridizes to a viral target RNA sequence comprising or consisting essentially of at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 contiguous nucleotides located within positions 180 to 215, 230 to 270, 350 to 420, 675 to 730, 1165 to 1210, 1245 to 1290, 1400 to 1480, or 1500 to 1630 of SEQ ID NO: 89. NO: 89 position 191, 245, 246, 276, 376, 377, 381, 383, 694, 700, 1182, 1261, 1262, 1408, 1410, 1426, 1431, 1432, 1433, 1435, 1438, 1441, 1443, 1513, 1516, 1517, 1518, 1519, 1520, 1521, 1522, 1527, 1559, 1575, 1576, 1577, 1580, 1581, 1582 or 1589 starting consecutive nucleotides. In some embodiments, the central region is fully complementary to the viral target RNA sequence. In some embodiments, there are less than or equal to 5, 4, 3, 2 or 1 mismatches between the central region and the viral target sequence.In some embodiments, there are less than or equal to 2 mismatches between the central region and the viral target sequence. In some embodiments, there are less than or equal to 1 mismatch between the central region and the viral target sequence.
[0133] In some embodiments, the ASO comprises a nucleotide sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or 100% identical to a nucleotide sequence selected from the sequences listed in Table 1.
[0134] In some embodiments, the ASOs of the present disclosure may have a sequence that differs from the ASOs of Table 1 by one nucleoside. In some embodiments, the ASOs of the present disclosure may have a sequence that differs from the ASOs of Table 1 by two nucleosides. In some embodiments, the ASOs of the present disclosure may have a sequence that differs from the ASOs of Table 1 by three nucleosides. In some embodiments, the ASOs of the present disclosure may have a sequence that differs from the ASOs of Table 1 by four nucleosides.
[0135] In some embodiments, the ASO of the present disclosure may have a sequence of Table 1, but one T in the central region is replaced by (2s)T, one C in the central region is replaced by (5OH)C, and / or the A in the central region is replaced by (8nh)A. In some embodiments, the ASO of the present disclosure may have a sequence of Table 1, but have one or two ScpBNA, AmNA or GuNA in the 5' wing portion. In some embodiments, the ASO of the present disclosure may have a sequence of Table 1, but have one or two ScpBNA, AmNA or GuNA in the 3' wing portion. In some embodiments, the ASO of the present disclosure may have a sequence of Table 1, but mA or mU is appended to the 5' end of the sequence. In some embodiments, the ASOs of the present disclosure may have the sequence of Table 1, but mA or mU is appended to the 5' end of the sequence, the 3' end of the sequence, or both, which is linked to a GalNAc derivative (e.g., GalNAc4, such as GalNAc4-(PS)2-p-; or GalNAc6, such as GalNAc6-(PS)2-p-), as described in detail herein.
[0136] In some embodiments, the ASO comprises a nucleotide sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or 100% identical to the nucleotide sequence of any one of SEQ ID NOs: 1-88.
[0137] In some embodiments, the ASO of the present invention has a sequence that differs from any one of the nucleotides of SEQ ID NOs: 1-88 by one nucleoside. In other embodiments, the ASO has a sequence that differs from any one of the nucleotides of SEQ ID NOs: 1-88 by 1, 2, 3 or 4 nucleosides. In some embodiments, the ASO of the present invention has a sequence of any one of SEQ ID NOs: 1-88, but one T in the central region is replaced by (2s) T, one C in the central region is replaced by (5OH) C, and / or one A in the central region is replaced by (8nh) A. In some embodiments, the ASO of the present invention has a sequence of any one of SEQ ID NOs: 1-88, but has one or two ScpBNAs, AmNAs or GuNAs in the 5' wing portion. In some embodiments, the ASO of the present invention has a sequence of any one of SEQ ID NOs: 1-88, but has one or two ScpBNAs, AmNAs or GuNAs in the 3' wing portion. In some embodiments, the ASO of the present disclosure has a sequence of any one of SEQ ID NOs: 1-88, but mA or mU is appended to the 5' end of the sequence. In some embodiments, the ASO of the present disclosure has a sequence of any one of SEQ ID NOs: 1-88, but mA or mU is appended to the 5' end of the sequence, which is connected to a GalNAc derivative (e.g., GalNAc4, such as GalNAc4-(PS)2-p-; or GalNAc6, such as GalNAc6-(PS)2-p-), as described in detail herein.
[0138] Target RNA sequence
[0139] The disclosed ASOs can reduce the expression of a target RNA sequence (e.g., a target gene) by recruiting RNase H to cleave and degrade the RNA transcript of the target RNA sequence, reducing RNA levels, and thereby reducing the levels of protein encoded by the target RNA sequence.
[0140] For the purposes of this disclosure, the target RNA sequence can be any gene in a cell. In some embodiments, the target gene is a viral gene. In some embodiments, the viral gene is from a DNA virus. In some embodiments, the DNA virus is a double-stranded DNA (dsDNA) virus. In some embodiments, the dsDNA virus is a hepadnavirus. In some embodiments, the hepadnavirus is hepatitis B virus (HBV). In some embodiments, HBV is selected from HBV genotypes AJ. In some embodiments, viral diseases are caused by RNA viruses. In some embodiments, RNA viruses are single-stranded RNA viruses (ssRNA viruses). In some embodiments, ssRNA viruses are positive single-stranded RNA viruses ((+)ssRNA viruses). In some embodiments, (+)ssRNA viruses are coronaviruses. In some embodiments, coronaviruses are beta-coronaviruses. In some embodiments, beta coronavirus is selected from the group consisting of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (also referred to as the temporary name 2019 novel coronavirus or 2019-nCoV), human coronavirus OC43 (hCoV-OC43), Middle East respiratory syndrome-related coronavirus (MERS-CoV, also referred to as the temporary name 2012 novel coronavirus or 2012-nCoV) and severe acute respiratory syndrome-related coronavirus (SARS-CoV, also referred to as SARS-CoV-1). In some embodiments, beta coronavirus is SARS-CoV-2, i.e., the pathogen of COVID-19. Some exemplary target genes are shown in Table 6 at the end of the specification.
[0141] In some embodiments, the target RNA sequence is selected from the S gene or X gene of HBV. In some embodiments, HBV has a genome sequence shown in the nucleotide sequence of SEQ ID NO: 90, which corresponds to the nucleotide sequence of GenBank Accession No. U95551.1, which is incorporated herein by reference in its entirety.
[0142] An exemplary HBV genomic sequence is shown in SEQ ID NO:89, corresponding to Genbank Accession No. KC315400.1, which is incorporated herein by reference in its entirety. Nucleotides 2307..3215, 1..1623 of SEQ ID NO:89 correspond to the polymerase / RT gene sequence encoding for the polymerase protein. Nucleotides 2848..3215, 1..835 of SEQ ID NO:89 correspond to the PreS1 / S2 / S gene sequence, which encodes the large S protein. Nucleotides 3205..3215, 1..835 of SEQ ID NO:89 correspond to the PreS2 / S gene sequence, which encodes the intermediate S protein. Nucleotides 155..835 of SEQ ID NO:89 correspond to the S gene sequence, which encodes the small S protein. Nucleotides 1374..1838 of SEQ ID NO:89 correspond to the X gene sequence, which encodes the X protein. Nucleotides 1814..2452 of SEQ ID NO:89 correspond to the PreC / C gene sequence, which encodes the precore / core protein. Nucleotides 1901..2452 of SEQ ID NO:89 correspond to the C gene sequence, which encodes the core protein. The HBV genome further comprises viral regulatory elements, such as viral promoters (preS2, preS1, Core and X) and enhancer elements (ENH1 and ENH2). Nucleotides 1624..1771 of SEQ ID NO:89 correspond to ENH2. Nucleotides 1742..1849 of SEQ ID NO:60 correspond to the core promoter. Nucleotides 1818...3215,1..1930 of SEQ ID NO:89 correspond to pregenomic RNA (pgRNA), which encodes the core protein and polymerase protein.
[0143] In some embodiments, the target RNA sequence is selected from the genome of SARS-CoV. In some embodiments, SARS-CoV has a genome corresponding to the nucleotide sequence of GenBank Accession No. NC_004718.3, which is incorporated herein by reference in its entirety.
[0144] In some embodiments, the target RNA sequence is selected from the genome of MERS-CoV. In some embodiments, MERS-CoV has a genome corresponding to the nucleotide sequence of GenBank Accession No. NC_019843.3, which is incorporated herein by reference in its entirety.
[0145] In some embodiments, the target RNA sequence is selected from the genome of hCoV-OC43. In some embodiments, hCoV-OC43 has a genome corresponding to the nucleotide sequence of GenBank Accession No. NC_006213.1, which is incorporated herein by reference in its entirety.
[0146] In some embodiments, the target RNA sequence is selected from the genome of SARS-CoV-2. In some embodiments, SARS-CoV-2 has a genome sequence corresponding to the nucleotide sequence of GenBank Accession No. NC_045512.2, which is incorporated herein by reference in its entirety.
[0147] In some embodiments, the target RNA sequence can be any hydroxysteroid dehydrogenase gene. In any embodiment, the gene is hydroxysteroid 17-β dehydrogenase 13 (HSD17B13). HSD17B13 has a sequence shown in the nucleotide sequence of SEQ ID NO:91, which corresponds to the nucleotide sequence (nucleotides 42 to 944) of the coding sequence of GenBank accession number NM_178135.5, which is incorporated herein by reference in its entirety.
[0148] In some embodiments, the target RNA sequence is at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% identical to a region of nucleotides within SEQ ID NO: 91, except that thymine (T) is replaced with uracil (U) in SEQ ID NO: 91. In some embodiments, the first nucleotide sequence is at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% identical to nucleotides 15 to 30, 15 to 25, 15 to 23, 15 to 22, 15 to 21, 17 to 25, 17 to 23, 17 to 22, 17 to 21, or 19 to 21 within SEQ ID NO: 91.
[0149] In some embodiments, the target RNA sequence is involved in liver metabolism. In some embodiments, the target RNA sequence is an inhibitor of the electron transport chain. In some embodiments, the target gene encodes a MCJ protein (MCJ / DnaJC15 or a methylation-controlled J protein). In some embodiments, the MCJ protein is encoded by the mRNA sequence of SEQ ID NO: 92, which corresponds to the nucleotide sequence of GenBank Accession No. NM_013238.3, which is incorporated herein by reference in its entirety.
[0150] In some embodiments, the target RNA sequence is TAZ. In some embodiments, TAZ comprises the nucleotide sequence of SEQ ID NO: 93, which corresponds to the nucleotide sequence of GenBank Accession No. NM_000116.5, which is incorporated herein by reference in its entirety.
[0151] In some embodiments, the target RNA sequence is angiopoietin-like 3 (ANGPTL3). In some embodiments, ANGPTL3 comprises the nucleotide sequence of SEQ ID NO: 94, which corresponds to the nucleotide sequence of GenBank Accession No. NM_014495.4, which is incorporated herein by reference in its entirety.
[0152] In some embodiments, the target RNA sequence is diacylglycerol acyltransferase 2 (DGAT2). In some embodiments, DGAT2 comprises the nucleotide sequence of SEQ ID NO: 95, which corresponds to the nucleotide sequence of GenBank Accession No. NM_001253891.1, which is incorporated herein by reference in its entirety.
[0153] Conjugated part
[0154] The present disclosure also relates to additional components conjugated to the ASO, such as targeting moieties and oligonucleotides modified at one or more ends. In some embodiments, the conjugated moiety is selected from galactosamine, peptides, proteins, sterols, lipids, phospholipids, biotin, phenoxazine, active drug substances, cholesterol, phenanthridine, anthraquinone, acridine, fluorescein, rhodamine, coumarin, folic acid, and dyes.
[0155] In some embodiments, the targeting moiety may comprise carbohydrates, such as monosaccharides, e.g., N-acetylgalactosamine (GalNAc), disaccharides, trisaccharides, tetrasaccharides, oligosaccharides, and polysaccharides. In some embodiments, the targeting moiety is optionally attached to one or more GalNAc derivatives of the ASO in a continuous structure via one or more linkers, such as two or three GalNAc derivatives. In certain embodiments, the targeting moiety comprises three consecutive GalNAc moieties attached via a linker, such as:
[0156]
[0157] In some embodiments, the conjugated moiety is galactosamine. In some embodiments, any of the ASOs disclosed herein is attached to a conjugated moiety that is galactosamine. In some embodiments, the galactosamine is N-acetylgalactosamine (GalNAc). In some embodiments, any of the ASOs disclosed herein comprises GalNAc. In some embodiments, GalNAc is of formula (VI):
[0158]
[0159] Wherein m is 1, 2, 3, 4 or 5; each n is independently 1 or 2; p is 0 or 1; each R is independently H or a first protecting group; each Y is independently selected from -OP(=O)(SH)-, -OP(=O)(O)-, -OP(=O)(OH)-, -OP(S)S- and -O-; Z is H or a second protecting group; L is a linker or L and Y are in combination a linker; and A is H, OH, a third protecting group, an activating group or an oligonucleotide. In some embodiments, the first protecting group is an acetyl group. In some embodiments, the second protecting group is a trimethoxytrityl group (TMT). In some embodiments, the activating group is a phosphoramidite group. In some embodiments, the phosphoramidite group is a cyanoethoxy N,N-diisopropylphosphoramidite group. In some embodiments, the linker is a C6-NH2 group. In some embodiments, A is ASO. In some embodiments, R is H, Z is H, and n is 1. In some embodiments, R is H, Z is H, and n is 2.
[0160] In some embodiments, GalNAc is of formula (VII):
[0161]
[0162] Where R z is OH or SH; and each n is independently 1 or 2. In some embodiments, the targeting ligand can be a GalNAc targeting ligand, which can contain 1, 2, 3, 4, 5 or 6 GalNAc units. In some embodiments, the targeting ligand can be a GalNAc selected from GalNAc2, GalNAc3, GalNAc4, GalNAc5 and GalNAc6.
[0163] In some embodiments, GalNAc can be GalNAc amide, GalNAc 4CPG, GalNAc phosphoramidite or GalNAc4-ps-GalNAc4-ps-GalNAc4. These GalNAc moieties are as follows:
[0164]
[0165]
[0166] GalNAc3, GalNAc4, GalNAc5 and GalNAc6 can be conjugated to the ASOs disclosed herein during synthesis using 1, 2 or 3 moieties. Other GalNAc moieties, such as GalNAc1 and GalNAc2, can be used to form 5' and 3'-GalNAc using post-synthesis conjugation.
[0167] GalNAc phosphoramidite
[0168]
[0169]
[0170] In some embodiments, the ASO contains a targeting moiety at the 5' end, 3' end or both ends of the ASO. The conjugated moiety can be attached to the ASO via 1, 2, 3, 4 or 5 or more joints. In some embodiments, the one or more joints are independently selected from the group consisting of: phosphodiester (p or po) joints, phosphorothioate (ps) joints, mesylphosphoamide joints (yp), phosphoramidite (HEG) joints, triethylene glycol (TEG) joints and / or dithiophosphate joints. In some embodiments, the one or more joints are independently selected from the group consisting of: p-(PS)2, (PS)2-p-TEG-p, (PS)2-p-HEG-p and (PS)2-p-(HEG-p)2.
[0171] In some embodiments, the conjugated moiety is a lipid moiety. In some embodiments, any of the ASOs disclosed herein is attached to a conjugated moiety as a lipid moiety. Examples of lipid moieties include, but are not limited to, a cholesterol moiety, a thioether (e.g., hexyl-S-tritylthiol), a thiocholesterol, an aliphatic chain (e.g., dodecyl glycol or undecyl residues), a phospholipid (e.g., di-hexadecyl-rac-glycerol or 1-di-O-hexadecyl-rac-tripropyl-SH-phosphonic acid triethylammonium), a polyamine or polyethylene glycol chain, adamantaneacetic acid, a palmityl moiety or octadecylamine or a hexylamino-carbonyl-hydroxycholesterol moiety.
[0172] In some embodiments, the conjugated moiety is an active drug substance. In some embodiments, any of the ASOs disclosed herein is attached to a conjugated moiety that is an active drug substance. Examples of active drug substances include, but are not limited to, aspirin, warfarin, phenylbutazone, ibuprofen, suprofen, fenbufen, ketoprofen, (5)-(+)-pranoprofen, carprofen, dansylsarcosine, 2,3,5-triiodobenzoic acid, flufenamic acid, folinic acid, benzothiadiazine, chlorothiazide, diazepine, indomethacin, barbiturate, cephalosporin, sulfonamide, antidiabetic, antibacterial, or antibiotic.
[0173] Exemplary ASOs
[0174] As described above, the ASOs disclosed herein may comprise modified nucleotides such as Gutb, Nmln, 5prnl, G-clamps, or combinations thereof. Additionally or alternatively, the ASOs disclosed herein may comprise at least one methylsulfonylphosphoramidate internucleoside bond. Table 1 provides some exemplary ASOs comprising modified nucleotides such as Gutb, Nmln, 5prnl, G-clamps, or combinations thereof; at least one methylsulfonylphosphoramidate internucleoside bond (referred to as "yp" in the sequence); or combinations thereof.
[0175] Table 1 - Exemplary ASO sequences
[0176]
[0177]
[0178]
[0179]
[0180] In Table 1, the nucleosides in bold contain one of the following modifications:
[0181]
[0182]
[0183] Pharmaceutical composition
[0184] The present disclosure also encompasses pharmaceutical compositions comprising the ASOs of the present disclosure. One embodiment is a pharmaceutical composition comprising one or more ASOs of the present disclosure and a pharmaceutically acceptable diluent or carrier.
[0185] In some embodiments, pharmaceutical compositions containing the ASOs of the present disclosure are formulated for systemic administration via parenteral delivery. Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal, or intramuscular injection or infusion; subcutaneous administration may also be performed, for example, via an implant device. In preferred embodiments, pharmaceutical compositions containing the ASOs of the present disclosure are formulated for subcutaneous (SC) or intravenous (IV) delivery. Formulations for parenteral administration may include sterile aqueous solutions, which may also contain buffers, diluents, and other pharmaceutically acceptable additives as understood by those skilled in the art. For intravenous use, the total concentration of solutes may be controlled to make the formulation isotonic.
[0186] Pharmaceutical compositions containing the ASOs of the present disclosure can be used to treat, for example, diseases or disorders associated with the expression or activity of HBV genes.
[0187] In some embodiments, the pharmaceutical composition comprises a first ASO of the present disclosure that is complementary or hybridized to a viral target RNA sequence in the first X region of HBV, and a second ASO of the present disclosure that is complementary or hybridized to a viral target RNA sequence in the second X region or S region of HBV, and a pharmaceutically acceptable diluent or carrier. When the pharmaceutical composition comprises two or more ASOs, the ASOs may be present in different amounts. For example, in some embodiments, the weight ratio of the first ASO to the second ASO is 1:4 to 4:1, such as 1:4, 1:3, 1:2, 1:1, 2:1, 3:1 or 4:1. In some embodiments, the molar ratio of the first ASO to the second ASO is 1:4 to 4:1, such as 1:4, 1:3, 1:2, 1:1, 2:1, 3:1 or 4:1.
[0188] treat
[0189] The siNA molecules and compositions described herein can be administered to a subject to treat a disease. Further disclosed herein is the use of any of the siNA molecules or compositions disclosed herein in the manufacture of a medicament for treating a disease. Specifically, the present disclosure provides ASOs for treating various diseases, such as infectious diseases, including but not limited to viral diseases and liver diseases.
[0190] One aspect of the present disclosure includes methods for treating subjects diagnosed with, suspected of having, or at risk of having HBV infection and / or HBV-related conditions. In therapeutic applications, a composition comprising at least one disclosed ASO is administered to a subject suspected of or already having such a disease (such as, for example, the persistent presence of HBV cccDNA, the presence of HBV antigens (e.g., HBsAg and / or HBeAg) in the subject's serum and / or liver, or elevated HBV viral load levels) in an amount sufficient to cure or at least partially arrest the disease, including its complications and intermediate pathological phenotypes in the development of the disease.
[0191] Subjects with HBV infection and / or HBV-related disorders can be identified by any one or a combination of diagnostic or prognostic assays known in the art. For example, typical symptoms of HBV infection and / or HBV-related disorders include, but are not limited to, the presence of hepatic HBV cccDNA, the presence of serum and / or hepatic HBV antigens (e.g., HBsAg and / or HBeAg), elevated ALT, elevated AST, absence or low levels of anti-HBV antibodies, liver damage, cirrhosis, hepatitis D, acute hepatitis B, acute fulminant hepatitis B, chronic hepatitis B, liver fibrosis, end-stage liver disease, hepatocellular carcinoma, serum sickness-like syndrome, anorexia, nausea, vomiting, low-grade fever, myalgia, easy fatigability, taste and olfactory disturbances (aversion to food and cigarettes), right upper quadrant and epigastric pain (intermittent, mild to moderate), hepatic encephalopathy, lethargy, sleep pattern disturbances, confusion, coma, ascites, gastrointestinal bleeding, coagulation disorders, jaundice, hepatomegaly (mild enlargement, soft liver), splenomegaly, palmar erythema, spider angiomas, muscle atrophy, spider-like hemangiomas, vasculitis, variceal bleeding, peripheral edema, gynecomastia, testicular atrophy, abdominal collateral veins (caput medusae), high levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) (in the range of 1000 - 2000 IU / mL), ALT levels higher than AST levels, elevated levels of γ-glutamyl transpeptidase (GGT) and / or alkaline phosphatase (ALP), decreased albumin levels, elevated serum iron levels, leukopenia (i.e., granulocytopenia), lymphocytosis, increased erythrocyte sedimentation rate (ESR), shortened red blood cell survival, hemolysis, thrombocytopenia, prolonged international normalized ratio (INR), presence of serum HBV DNA, elevated transaminases (< 5-fold ULN), elevated bilirubin levels, prolonged prothrombin time (PT), hyperglobulinemia, presence of tissue-nonspecific antibodies (such as anti-smooth muscle antibody (ASMA) or antinuclear antibody (ANA)), presence of tissue-specific antibodies (such as antibodies against the thyroid), elevated levels of rheumatoid factor (RF), hyperbilirubinemia, low platelet and white blood cell counts, AST levels higher than ALT levels, lobular inflammation with degenerative and regenerative hepatocyte changes, and predominantly centrilobular necrosis.
[0192] In some embodiments, subjects treated with the disclosed ASOs will exhibit improvement or elimination of one or more of the following conditions or symptoms: presence of hepatic HBV cccDNA, presence of serum and / or hepatic HBV antigens (e.g., HBsAg and / or HBeAg), lack of or low levels of anti-HBV antibodies, liver damage, cirrhosis, hepatitis D, acute hepatitis B, acute fulminant hepatitis B, chronic hepatitis B, liver fibrosis, end-stage liver disease, hepatocellular carcinoma, serum sickness-like syndrome, anorexia, nausea, vomiting, low-grade fever, myalgia, easy fatigability, taste sensitivity and smell disturbances (aversion to food and cigarettes), right upper quadrant and epigastric pain (intermittent, mild to moderate), hepatic encephalopathy, somnolence, disturbances in sleep patterns, confusion, coma , ascites, gastrointestinal bleeding, coagulopathy, jaundice, hepatomegaly (mild enlargement, soft liver), splenomegaly, palmar erythema, spider nevus, muscular atrophy, spider angiomas, vasculitis, varicose bleeding, peripheral edema, gynecomastia, testicular atrophy, abdominal collateral veins (cephalothorax), ALT levels higher than AST levels, leukopenia (i.e., granulocytopenia), decreased albumin levels, increased serum iron levels, lymphocytosis, increased erythrocyte sedimentation rate (ESR), shortened red blood cell survival, hemolysis, thrombocytopenia, prolonged international normalized ratio (INR), serum HBV The presence of DNA, prolonged prothrombin time (PT), hyperglobulinemia, the presence of tissue nonspecific antibodies (such as anti-smooth muscle antibodies (ASMA) or antinuclear antibodies (ANA)), the presence of tissue specific antibodies (such as anti-thyroid antibodies), hyperbilirubinemia, low platelet and white blood cell counts, AST levels higher than ALT levels, lobular inflammation with degenerative and regenerative hepatocellular changes, and predominantly centrilobular necrosis.
[0193] The present disclosure provides a method for treating a subject diagnosed with or suspected of having HBV infection and / or HBV-related illness, comprising administering an effective amount of an ASO composition of the present disclosure to the subject. In some embodiments, the method comprises administering to the subject a first ASO of the present disclosure and a second ASO of the present disclosure, wherein the first ASO is complementary to or hybridizes with a viral target RNA sequence in a first X region of HBV, and the second ASO is complementary to or hybridizes with a viral target RNA sequence in a second X region or S region of HBV. In some embodiments, the second ASO is complementary to or hybridizes with a viral target RNA sequence in a second X region of HBV. In other embodiments, the second ASO is complementary to or hybridizes with a viral target RNA sequence in the S region of HBV.
[0194] In some embodiments of the disclosed methods and uses, the disease is a respiratory disease. In some embodiments, the respiratory disease is a viral infection. In some embodiments, the respiratory disease is viral pneumonia. In some embodiments, the respiratory disease is an acute respiratory infection. In some embodiments, the respiratory disease is a cold. In some embodiments, the respiratory disease is severe acute respiratory syndrome (SARS). In some embodiments, the respiratory disease is Middle East respiratory syndrome (MERS). In some embodiments, the disease is coronavirus disease 2019 (e.g., COVID-19). In some embodiments, respiratory diseases may include one or more symptoms selected from the following: cough, sore throat, runny nose, sneezing, headache, fever, shortness of breath, myalgia, abdominal pain, fatigue, dyspnea, persistent chest pain or pressure, difficulty waking up, loss of smell and taste, muscle or joint pain, chills, nausea or vomiting, nasal congestion, diarrhea, hemoptysis, conjunctival congestion, expectoration, chest tightness and palpitations. In some embodiments, respiratory diseases may include complications selected from sinusitis, otitis media, pneumonia, acute respiratory distress syndrome, disseminated intravascular coagulation, pericarditis and renal failure. In some embodiments, the respiratory disease is idiopathic.
[0195] In some embodiments, the present disclosure provides a method for treating or preventing coronavirus infection, comprising administering a therapeutically effective amount of one or more ASOs or pharmaceutical compositions disclosed herein to a subject in need thereof. In some embodiments, coronavirus infection is selected from the group consisting of: Middle East Respiratory Syndrome (MERS), Severe Acute Respiratory Syndrome (SARS), and COVID-19. In some embodiments, the subject has been treated with one or more additional coronavirus therapeutic agents. In some embodiments, the subject is treated with one or more additional coronavirus therapeutic agents simultaneously.
[0196] In some embodiments, the disease is a liver disease. In some embodiments, the liver disease is non-alcoholic fatty liver disease (NAFLD). In some embodiments, NAFLD is non-alcoholic steatohepatitis (NASH). In some embodiments, the liver disease is hepatocellular carcinoma (HCC).
[0197] The ASOs of the present disclosure can be used to treat a disease in a subject in need thereof. In some embodiments, a method of treating a disease in a subject in need thereof comprises administering to the subject any of the ASOs disclosed herein. In some embodiments, a method of treating a disease in a subject in need thereof comprises administering to the subject any of the compositions disclosed herein.
[0198] Administration of ASOs can be performed by methods known in the art. In some embodiments, ASOs are administered by subcutaneous (SC) or intravenous (IV) delivery. The formulations (e.g., ASOs or compositions) disclosed herein can be administered orally, parenterally, topically, or rectally. Of course, they are administered in a form suitable for each route of administration. For example, they are administered in tablet or capsule form, administered by injection, infusion, or inhalation; topically by lotion or ointment; and rectally by suppository. In some embodiments, subcutaneous administration is preferred.
[0199] As used herein, the phrases "parenteral administration" and "administered parenterally" refer to modes of administration other than enteral and topical administration, which are usually administered by injection, and include, but are not limited to, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, intratracheal, subcutaneous, subcutaneous, intraarticular, subcapsular, subarachnoid, intraspinal, and intrasternal injection and infusion.
[0200] As used herein, the phrases "systemic administration," "administered systemically," "peripheral administration," and "administered peripherally" refer to the administration of a compound, drug, or other material other than directly into the central nervous system so that it enters the patient's system and is thus subject to metabolism and other similar processes, e.g., subcutaneous administration.
[0201] The compounds can be administered to humans and other animals for therapy by any suitable route of administration, including oral, nasal (e.g., by spray), rectal, vaginal, parenteral, intracisternal, and topical (e.g., by powders, ointments or drops), including buccal and sublingual.
[0202] Regardless of the route of administration selected, the compounds of the disclosure (eg, ASOs) and / or pharmaceutical compositions of the disclosure, which may be used in a suitable hydrated form, are formulated into pharmaceutically acceptable dosage forms by conventional methods known to those skilled in the art.
[0203] Actual dosage levels of the active ingredients in the pharmaceutical compositions of the present disclosure may be varied so as to obtain an amount of the active ingredient that is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without causing toxicity to the patient.
[0204] The selected dosage level will depend upon a variety of factors including the activity of the particular compound of the disclosure (e.g., ASO) employed, or an ester, salt or amide thereof, the route of administration, the time of administration, the rate of excretion or metabolism of the particular compound employed, the rate and extent of absorption, the duration of the treatment, other drugs, compounds and / or materials used in combination with the particular compound employed, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and like factors well known in the medical arts.
[0205] A physician or veterinarian having ordinary skill in the art can readily determine and prescribe the effective amount of the desired pharmaceutical composition. For example, a physician or veterinarian can start the dosage of the disclosed compound (e.g., ASO) used in the pharmaceutical composition at a level lower than the level required to achieve the desired therapeutic effect, and gradually increase the dosage until the desired effect is achieved.
[0206] In general, the suitable daily dose of a compound of the present disclosure (e.g., ASO) is the amount of the compound at the lowest dose that effectively produces a therapeutic effect. Such effective doses generally depend on the above factors. Preferably, the compound is administered at about 0.01 mg / kg to about 200 mg / kg, more preferably at about 0.1 mg / kg to about 100 mg / kg, and even more preferably at about 0.5 mg / kg to about 50 mg / kg. In some embodiments, the compound is administered at about 1 mg / kg to about 40 mg / kg, about 1 mg / kg to about 30 mg / kg, about 1 mg / kg to about 20 mg / kg, about 1 mg / kg to about 15 mg / kg, or 1 mg / kg to about 10 mg / kg. In some embodiments, the compound is administered at a dose equal to or greater than 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.10, 0.11, 0.12, 0.13, 0.14, 0.15, 0.16, 0.17, 0.18, 0.19, 0.20, 0.21, 0.22, 0.23, 0.24, 0.25, 0.26, 0.27, 0.28, 0.29, 0.30, 0.35, 0.40, 0.45, 0.50, 0.55, 0.60, 0.65, 0.7, 0.75, 0.8, 0.85, 0.9, 0.95, or 1 mg / kg. In some embodiments, the compound is administered at a dose equal to or greater than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 mg / kg. In some embodiments, the compound is administered at a dose equal to or less than 200, 190, 180, 170, 160, 150, 140, 130, 120, 110, 100, 95, 90, 85, 80, 75, 70, 65, 60, 55, 50, 45, 40, 35, 30, 25, 20, or 15 mg / kg. In some embodiments, the total daily dose of the compound is equal to or greater than 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, or 100 mg.
[0207] If desired, the effective daily dose of the active compound (e.g., ASO) can be administered as two, three, four, five, six, seven, eight, nine, ten or more doses or sub-doses at appropriate intervals throughout the day, optionally in unit dosage form. In some embodiments, the compound is administered at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 times. The preferred dosage is once a day. In some embodiments, the compound is administered at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or 21 times a week. In some embodiments, the compound is administered at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or 21 times a month. In some embodiments, the compound is administered once every 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or 21 days. In some embodiments, the compound is administered every 3 days. In some embodiments, the compound is administered once every 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 weeks. In some embodiments, the compound is administered monthly. In some embodiments, the compound is administered once every 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 months. In some embodiments, at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62 43, 44, 45, 46, 47, 48, 49, 50, 51, 52 or 53 administrations of a compound within a period of at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52 or 53 administrations within a period of at least 1, 2, 3, 4, 5In some embodiments, at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, or 53 weeks The compound is administered at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52 or 53 times over a period of time. In some embodiments, the patient is at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, or 53 months. 43, 44, 45, 46, 47, 48, 49, 50, 51, 52 or 53 administrations of the compound over a period of time. In some embodiments, the compound is administered at least once a week for a period of at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, or 70 weeks.In some embodiments, the compound is administered at least once a week for a period of at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, or 70 months. In some embodiments, the compound is administered at least twice a week for a period of at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, or 70 weeks. In some embodiments, the compound is administered at least twice a week for a period of at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, or 70 months. In some embodiments, the compound is administered at least once every two weeks for a period of at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, or 70 weeks.In some embodiments, the compound is administered at least once every two weeks for a period of at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, or 70 months. In some embodiments, the compound is administered at least once every four weeks for a period of at least 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, or 70 weeks. In some embodiments, the compound is administered at least once every four weeks for a period of at least 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, or 70 months.
[0208] The subject of the method can be a mammal, and includes humans and non-human mammals. In some embodiments, the subject is a human, such as an adult.
[0209] Some embodiments include a method for treating HBV virus in a subject infected with the virus, the method comprising administering to a subject in need thereof a therapeutically effective amount of one or more ASOs of the present disclosure or a composition of the present disclosure, thereby reducing the viral load in the subject and / or reducing the level of viral antigens in the subject. The ASO may be complementary or hybridize to a portion of the target RNA in the virus, such as the second X region and / or the S region of HBV.
[0210] In some embodiments, the modified oligonucleotides described herein can be used in combination with one or more additional agents for treating and / or inhibiting HBV and / or HDV replication. When the compound described herein (e.g., ASO) is co-administered with an additional agent, the effective amount may be lower than the effective amount when the compound is used alone. Additional agents include, but are not limited to, interferon, nucleoside / nucleotide analogs, capsid assembly regulators (CAMs), siRNA, other ASOs, nucleic acid polymers or S-antigen transport inhibitory oligonucleotide polymers (NAPs or STOPS), entry inhibitors and / or small molecule immunomodulators. Examples of additional agents include ALG-010133, ALG-000184, recombinant interferon alpha 2b, IFN-a, PEG-IFN-a-2a, lamivudine, telbivudine, adefovir dipivoxil, clavudine, entecavir, tenofovir alafenamide, tenofovir disoproxil, NVR3-778, BAY41-4109, JNJ-632, JNJ-3989 (ARO-HBV) , RG6004, GSK3228836, REP-2139, REP-2165, AB-729, VIR-2218, DCR-HBVS, JNJ-6379, GLS4, ABI-HO731, JNJ-440, NZ-4, RG7907, EDP-514, AB-423, AB-506, ABI-H03733 and ABI-H2158. In some embodiments, any of the ASOs disclosed herein are co-administered with any of the STOPS. Exemplary STOPS are described in International Publication No. WO2020 / 097342 and U.S. Publication No. 2020 / 0147124, both of which are incorporated herein by reference in their entirety. In some embodiments, STOP is ALG-010133. In some embodiments, any of the ASOs disclosed herein are co-administered with tenofovir. In some embodiments, any of the ASOs disclosed herein are co-administered with a CAM. Exemplary CAMs are described in Berke et al., Antimicrob Agents Chemother, 2017, 61(8): e00560-17, Klumpp et al., Gastroenterology, 2018, 154(3): 652-662.e8, International Application Nos. PCT / US2020 / 017974, PCT / US2020 / 026116, and PCT / US2020 / 028349, and U.S. Application Nos. 16 / 789,298, 16 / 837,515, and 16 / 849,851, each of which is incorporated herein by reference in its entirety. In some embodiments, the CAM is ALG-000184, ALG-001075, ALG-001024, JNJ-632, BAY41-4109, or NVR3-778.In some embodiments, the ASO and the additional agent are administered simultaneously. In some embodiments, the ASO and the additional agent are administered sequentially. In some embodiments, the ASO is administered prior to the administration of the additional agent. In some embodiments, the ASO is administered after the administration of the additional agent.
[0211] definition
[0212] As used herein, the terms "patient" and "subject" refer to an organism to be treated by the methods of the present disclosure. Such organisms are preferably mammals (e.g., marine animals, apes, equines, bovines, porcines, canines, felines, etc.), and more preferably humans.
[0213] As used herein, the term "effective amount" refers to an amount of a compound (e.g., an ASO of the present disclosure) sufficient to achieve a beneficial or desired result. An effective amount can be administered in one or more administrations, applications, or dosages and is not intended to be limited to a particular formulation or route of administration.
[0214] As used herein, the term "treating" includes any effect that results in improvement or amelioration of a condition, disease, disorder, or the like, or amelioration of the symptoms thereof, such as alleviation, reduction, regulation, improvement, or elimination.
[0215] As used herein, the terms "alleviate" and "alleviating" refer to reducing the severity of a condition, such as reducing the severity by, for example, at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 95%.
[0216] As used herein, the term "pharmaceutical composition" refers to the combination of an active agent with an inert or active carrier, making the composition particularly suitable for in vivo or ex vivo diagnostic or therapeutic use.
[0217] As used herein, the term "pharmaceutically acceptable carrier" refers to any of the standard pharmaceutical carriers, such as phosphate buffered saline solution, water, emulsions (e.g., such as oil / water or water / oil emulsions), and various types of wetting agents. The composition may also contain stabilizers and preservatives. For examples of carriers, stabilizers, and adjuvants, see, e.g., Martin, Remington's Pharmaceutical Sciences, 15th Edition, Mack Publ. Co., Easton, PA
[1975] .
[0218] As used herein, the term "about" when referring to a measurable value (e.g., weight, time, and dosage) is intended to encompass the recited value and a range of + / - 10%. For example, "about 10" should be understood as both "10" and "9 to 11".
[0219] As used herein, the term "nucleobase" or "base" refers to a nitrogen-containing biological compound that forms a nucleoside. Examples of nucleobases include, but are not limited to, thymine, uracil, adenine, cytosine, guanine, and analogs or derivatives thereof.
[0220] Throughout the specification, where compositions are described as having, including, or comprising specific components, or where processes and methods are described as having, including, or comprising specific steps, it is contemplated that the compositions of the present additional disclosure also consist essentially of, or consist of, the described components, and that the processes and methods according to the present disclosure also consist essentially of, or consist of, the described process steps.
[0221] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention belongs. Although any methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present invention, representative illustrative methods and materials are now described.
[0222] Where a range of values is provided, it is to be understood that each intervening value (to one tenth of the unit of the lower limit, unless expressly stated otherwise) between the upper and lower limits of the range, as well as any other stated or intermediate values in the range, is encompassed within the present invention. The upper and lower limits of these smaller ranges may be independently included in smaller ranges and are also encompassed within the present invention, subject to any explicitly excluded limits in the stated ranges. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also encompassed within the present invention.
[0223] The present disclosure is not limited to the particular embodiments described, as such may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present invention will be limited only by the appended claims.
[0224] Those skilled in the art will appreciate after reading this disclosure that each individual embodiment described and illustrated herein has discrete components and features that can be easily separated or combined with the features of any of the other several embodiments without departing from the scope or spirit of the invention. Any recorded method can be performed in the order of events recorded or in any other order that is logically possible.
[0225] All publications and patents cited in this specification are incorporated herein by reference, as if each individual publication or patent was specifically and individually indicated to be incorporated by reference, and are incorporated herein by reference to disclose and describe methods and / or materials related to the cited publications. Reference to any publication should not be construed as an admission that the present invention is not entitled to antedate such publications by virtue of prior invention. Further, the publication date provided may be different from the actual publication date, which may require independent confirmation.
[0226] Examples
[0227] The following examples illustrate certain embodiments of the present disclosure to help technicians practice the present disclosure. Accordingly, these examples are by no means considered to limit the scope of the present disclosure.
[0228] Example 1: ASO synthesis
[0229] Gap-Block ASO Sequence DNA, 2'-O-Me and LNA phosphoramidite monomers were purchased from commercial sources (Hongene Biotech USA Inc.). All monomers were dried in a vacuum dryer with a desiccant (P2O5, 24h at room temperature). The attached universal solid support (CPG) was obtained from ChemGenes. Chemicals and solvents used in the synthesis workflow were purchased from VWR / Sigma commercial sources and can be used without any purification or treatment. During the synthesis, solvents (acetonitrile) and solutions (amides (amidite) and activators) were stored on molecular sieves.
[0230] The control and target oligonucleotide sequences were synthesized on an Expedite 8909 synthesizer using standard cycles as written by the manufacturer, with some waiting steps and modified coupling steps modified. The solid support was controlled pore glass and the monomers contained standard protecting groups. Each chimeric oligonucleotide was synthesized using commercially available 5'-O-(4,4'-dimethoxytrityl)-3'-O-(2-cyanoethyl-N,N-diisopropyl)DNA, 2'-OMe and / or 6-N-benzoyladenosine (A Bz ), 5-methyl-4-N-benzamide (C Bz ), 2-N-isobutyrylguanosine (G iBu) and uridine (U) or thymidine (T) LNA phosphoramidite monomers were synthesized individually according to standard solid phase phosphoramidite synthesis protocols. 2'-O-Me-2,6-diaminopurine phosphoramidite was purchased from Glen Research. The phosphoramidite was prepared as a 0.1 M solution in anhydrous acetonitrile. 5-Ethylthiotetrazole was used as an activator, 3% dichloroacetic acid in dichloromethane was detritylated, acetic anhydride in THF and 16% N-methylimidazole in THF were used as end caps, and DDTT ((dimethylaminomethylene)amino)-3H-1,2,4-dithiazoline-3-thione) was used as a sulfur transfer agent for the synthesis of oligoribonucleotide thiophosphates. In the presence of 5-(ethylthio)-1H-tetrazole activator, a 0.1 M solution of phosphoramidite in CH3CN was extended to couple with the solid bound oligonucleotide, followed by extended capping, oxidation and deprotection to obtain the modified oligonucleotide. The stepwise coupling efficiency of all modified phosphoramidites was greater than 98.5%.
[0231] Deprotection and cleavage from the solid support were achieved using a mixture of aminomethylamine (1:1, AMA) for 15 min at 65° C. When a universal linker was used, deprotection was performed at 65° C. for 90 min, or the solid support was heated with ammonia (28%) solution at 55° C. for 8 h to deprotect base-labile protecting groups.
[0232] After the solid support was removed by filtration, the deprotection solution was removed in vacuo in a GeneVac centrifugal evaporator.
[0233]
[0234]
[0235] Locked Nucleic Acid (LNA) Phosphoramidites
[0236]
[0237] Example 2: Modified spacer sequences
[0238] AmNA(N-Me)-T, AmNA(N-Me)-4-N-benzoyl(5m)cytidine((5m)C Bz ), AmNA(N-Me)-4-N-benzoylcytidine (A Bz ) and AmNA(N-Me)-2-N-pac(G pac ) were purchased from Luxna Biotech, while scp-BNA-T, scp-BNA-6-N-benzoyl adenosine (A Bz ), scp-BNA-4-N-benzoyl-5-methylcytidine ((5m)C Bz), scp-BNA-2-N-isobutyrylguanosine (G iBu ) The phosphoramidite monomers were synthesized according to the procedures described in references (Takao Yamaguchi, Masahiko Horiba, and Satoshi Obika; Chem. Commun., 2015, 51, 9737-9740; Masahiko Horiba, Takao Yamaguchi, and Satoshi Obika; Journal of Organic Chemistry, 2016, 81, 11000-11008). All monomers were dried in a vacuum desiccator with a desiccant (KOH and P2O5, room temperature for 24 hours). In the case of AmNA(N-Me)-PS-DNA-PS and scp-BNA-PS-DNA-PS, the modification synthesis was carried out in the 3' to 5' direction using phosphoramidite monomers at 1 μM, diluted to 0.12M concentration in anhydrous CH3CN (coupling time 16 min) in the presence of 0.3M 5-(benzylthio)-1H-tetrazole activator to form solid-bound oligonucleotides, followed by modification capping, oxidation and deprotection to obtain modified oligonucleotides. The stepwise coupling efficiency of all modified phosphoramidites was greater than 97%. DDTT (dimethylaminomethylene)amino)-3H-1,2,4-dithiazoline-3-thione was used as a sulfur transfer agent for the synthesis of oligoribonucleotide thiophosphates. The solid support with oligonucleotides was washed with 20% DEA acetonitrile solution for 15 min, and the column was then washed thoroughly with MeCN. The support was heated with diisopropylamine:water:methanol (1:1:2) in a heating block at 65°C for 8 h to cleave and deprotect the base-labile protecting groups from the support.
[0239] AmNA(N-Me) monomer
[0240]
[0241] scp-BNA monomer
[0242]
[0243] 5' and 3'-GalNAc conjugated oligonucleotides are synthesized with GalNAc moieties of varying lengths, for example, as described below. GalNAc3, GalNAc4, GalNAc5, and GalNAc6 are conjugated to oligonucleotides during synthesis using 1, 2, or 3 moieties in the same manner as described below. Other GalNAc moieties, such as GalNAc-1 and GalNAc-2 described previously herein, can also be used to form 5' and 3'-GalNAc by post-synthesis conjugation.
[0244] GalNAc phosphoramidite
[0245]
[0246]
[0247] Quantitation or primary analysis of crude oligomers
[0248] The samples were dissolved in deionized water (1.0 mL) and quantified as follows: First, a blank was performed on the Nanodrop UV spectrophotometer with water only. The Nano Drop instrument can measure nucleic acids over a wide range of concentrations by using a variety of path lengths. The most accurate quantitative results can be obtained by measuring the absorbance of the diluted oligonucleotide at 260 nm. The crude material was stored at -20 °C.
[0249] Crude HPLC / LC-MS analysis
[0250] 0.1 OD of the crude sample was used for crude MS analysis. After confirmation of the crude LC-MS data, the purification steps were performed.
[0251] HPLC purification
[0252] Phosphodiester (PO), phosphorothioate (PS) and chimeric modified oligonucleotides were purified by anion exchange HPLC. The buffer was 20 mM sodium phosphate in 10% CH3CN, pH 8.5 (buffer A) and 20 mM sodium phosphate in 10% CH3CN, 1.8 M NaBr, pH 8.5 (buffer B). The fractions containing the full-length oligonucleotides were combined, desalted and lyophilized.
[0253] The lipid conjugated oligonucleotides were purified by RPC-Source 15 reverse phase columns packed in-house. The buffers were 10% CH3CN (buffer A) and 20 mM sodium acetate in CH3CN (buffer B). The fractions containing the full-length oligonucleotides were pooled, desalted and lyophilized.
[0254] Desalting of purified oligomers
[0255] The purified dried oligomers were then desalted using Sephadex G-25M (Amersham Biosciences). The cartridge was adjusted three times with 10 mL of deionized water. The purified oligonucleotides thoroughly dissolved in 2.5 mL of deionized water were applied to the cartridge with very slow dropwise elution. The salt-free oligomers were directly eluted into a screw cap vial with 3.5 ml of deionized water.
[0256] Final HPLC and electrospray LC / MS analysis
[0257] Approximately 0.10 OD of the oligomer was dissolved in water and then transferred into special vials for IEX-HPLC and LC / MS analysis.Analytical HPLC and ES LC-MS confirmed the integrity of the chimeric oligonucleotide.
[0258] Postsynthetic conjugation of GalNAc esters to oligonucleotides
[0259] Synthesis of 5'-C6-amino precursor
[0260] The sequences were synthesized at a 10 μmol scale using a universal support (loading 65 μmol / g). A C6-NH2 linker was introduced at the 5'-terminus using 6-(4-monomethoxytritylamino)hexyl-(2-cyanoethyl)-(N,N-diisopropyl)-phosphoramidite in 0.1 M acetonitrile with a coupling time of 10 min. The solid support with the oligonucleotide was heated with ammonia / methylamine (1:1) solution on a shaker at room temperature for 3 h to cleave from the support and deprotect the base-labile protecting groups. After IEX purification and desalting, the C6-NH2-modified ASOs were used for postsynthetic conjugation.
[0261]
[0262] GalNAc esters for conjugation
[0263]
[0264] Post-synthetic conjugation of 5'-GalNAc synthesis
[0265] The 5'-C6-NH2 modified sequence was dissolved in 0.2M sodium bicarbonate buffer, pH 8.5 (0.015mM), and 5-7mol equivalents of GalNAc ester dissolved in DMSO were added. The reaction mixture was stirred at room temperature for 4h. The sample was analyzed to confirm whether there was any unreacted amino-modified ASO. Ammonia water (28 wt%) (5× reaction volume) was added thereto and stirred at room temperature for 2-3h. The reaction mixture was concentrated under reduced pressure, and the residue was dissolved in water and purified by HPLC on a strong anion exchange column.
[0266] Example 3: In vitro analysis of HBsAg release assay
[0267] HepG2.2.15 cells (a stable cell line with four integrated HBV genomes) were maintained in DMEM medium containing 10% fetal bovine serum (FBS) and 1% penicillin / streptomycin, 1% glutamine, 1% non-essential amino acids, 1% sodium pyruvate and 250 μg / ml G418. Cells were maintained at 37°C in a 5% CO2 atmosphere. For the HBsAg release assay, the assay medium was prepared: DMEM containing 5% FBS, 1% penicillin / streptomycin, 1% glutamine and 1% DMSO. One day before the assay, the trypsinized HepG2.2.15 cells were washed once with assay medium, centrifuged at 250g x 5min, resuspended with assay medium, and seeded in 96-well plates coated with collagen at 50,000 cells / well in assay medium. The next day, ASO was diluted with Opti-MEM, 9-pt, 3-fold dilution and Lipofectamine RNAiMAX (Invitrogen) was diluted according to the manufacturer's manual. The ASO dilution and RNAiMAX dilution were mixed, left at room temperature for 5 minutes, and 15 μl was added to each well in a 96-well plate. The plate was placed in an incubator at 37°C, 5% CO2 for 5 days. After incubation, the supernatant was collected and HBsAg was measured using an ELISA kit (Diasino). Cell viability was measured using CellTiter-Glo (Promega). EC was calculated using PrismGraphpad 50 , which is the concentration of drug required to reduce HBsAg secretion by 50% relative to untreated cell controls. CC was calculated using the same software 50 , which is the concentration of drug required to reduce cell viability by 50% relative to untreated cell controls.
[0268] The obtained EC values of the compounds in Table 1 50 and CC 50 These are presented in Table 2 below. 50 and CC 50 Values are as follows: A: <1 nM, B: 1-10 nM, C: 10-100 nM, D: >100 nM.
[0269]
[0270]
[0271]
[0272] Additionally, the in vitro efficacy of some ASOs in HBV-infected primary human hepatocytes (PHH) was evaluated. Table 3 below provides exemplary EC values from these experiments. 50 and CC 50 data.
[0273]
[0274] Example 4: Melting Temperature (T m )
[0275] The melting temperatures of several exemplary ASOs disclosed herein were evaluated, and representative results are provided in Table 4 below.
[0276]
[0277] Example 5: Improvement of in vivo efficacy
[0278] ASOs with disclosed chemistry were synthesized on ABI 394 and Expedite 8909 synthesizers using standard phosphoramidite chemistry. In vitro screening of ASOs was performed in HepG2.2.15 cells using the HBsAg release assay as described above. Certain ASOs were selected for N-acetylgalactosamine (GalNac) conjugation and tested at a single dose of 1x5 mg / kg in an adeno-associated virus (AAV)-HBV mouse model.
[0279] Table 5 shows exemplary HBsAg nadirs for 1 x 5 mg / kg QW compared to ASO 59. In these ASOs in the HBx region, a single replacement of InA with nmlnA improved the HBsAg nadir for all HBV transcripts including HBx.
[0280]
[0281]
[0282] The figure shows an exemplary side-by-side comparison of ASO 59, the latter containing nmlnA, and ASO 87, the former containing InA. As can be seen in the figure, the addition of InmnA resulted in an improvement in potency.
[0283] *****
[0284] Table 6-Target gene sequences
[0285]
[0286]
[0287]
[0288]
[0289]
[0290]
[0291]
[0292]
[0293]
[0294]
Claims
1. An antisense oligonucleotide (ASO) comprising 14-22 nucleotide units, and: (a) a central region (B') comprising 6 or more consecutive DNA nucleotides; (b) a 5' wing (A') comprising 2 to 6 locked nucleotides or 2' substituted nucleosides; and (c) a 3' wing (C') comprising 2 to 6 locked nucleotides or 2' substituted nucleosides; wherein the central region of the ASO is at least 80% complementary or hybridizing to a target RNA sequence; and wherein the ASO comprises at least one modified nucleotide selected from: Where B is a nucleobase, Where B is a nucleobase, and 2. The ASO according to claim 1, wherein (i) the central region (B') comprises a modified nucleotide selected from the group consisting of G-clamp and 5prnl, (ii) the 5' wing region (A') comprises a modified nucleotide selected from the group consisting of Gutb and Nmln, (iii) the 3' wing region (C') comprises a modified nucleotide selected from the group consisting of Gutb and Nmln, or (iv) any combination thereof.
3. The ASO according to claim 1 or 2, wherein the central region (B') comprises 2, 3, 4, 5 or 6 or more modified nucleotides.
4. The ASO according to any one of claims 1 to 3, wherein the 5' wing (A'), the 3' wing (C') or both comprise a modified nucleotide selected from Gutb, Nmln, G-clamp and 5prnl.
5. The ASO molecule according to any one of claims 1 to 4, wherein the ASO molecule further comprises one or more phosphorothioate (ps) internucleoside bonds, methylsulfonylphosphoramidate (yp) internucleoside bonds, or a combination thereof.
6. The ASO molecule of any one of claims 1 to 5, wherein the ASO molecule further comprises at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 or 22 phosphorothioate (ps) internucleoside linkages, methylsulfonylphosphoramidate (yp) internucleoside linkages, or a combination thereof.
7. An antisense oligonucleotide (ASO) comprising 14-22 nucleotide units, wherein the ASO comprises: (a) a central region (B') comprising 6 or more consecutive DNA nucleotides, wherein at least one of the consecutive DNA nucleotides is a modified nucleotide, (b) a 5' wing (A') comprising 2 to 6 locked nucleotides or 2' substituted nucleosides, and (c) a 3' wing (C') comprising 2 to 6 locked nucleotides or 2' substituted nucleosides, wherein the central region of the ASO is at least 80% complementary or hybridizes to a target RNA sequence, and wherein the ASO comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or more methylsulfonylphosphoramidate (yp) internucleoside bonds.
8. The ASO of claim 7, wherein the ASO comprises at least 1, at least 2, at least 3, at least 4, or at least 5 or more nucleotides selected from: Where B is a nucleobase, Where B is a nucleobase, and 9. The ASO molecule according to claim 7 or 8, wherein the ASO molecule further comprises one or more phosphorothioate (ps) internucleoside bonds.
10. The ASO molecule according to any one of claims 1 to 9, wherein: (i) at least one methylsulfonyl phosphoramidate (yp) internucleotide bond is located from the ASO molecule to the between nucleoside positions 3 and 4 at the 5' end; (ii) at least one methylsulfonylphosphoramidate (yp) internucleotide linkage is located between nucleoside positions 5 and 6 from the 5' end of the ASO molecule; (iii) at least one methylsulfonylphosphoramidate (yp) internucleotide linkage is located between nucleoside positions 6 and 7 from the 5' end of the ASO molecule; (iv) at least one methylsulfonylphosphoramidate (yp) internucleotide linkage is located between nucleoside positions 7 and 8 from the 5' end of the ASO molecule; (v) at least one methylsulfonylphosphoramidate (yp) internucleotide linkage is located between nucleoside positions 8 and 9 from the 5' end of the ASO molecule; (vi) at least one methylsulfonylphosphoramidate (yp) internucleotide linkage is located between nucleoside positions 9 and 10 from the 5' end of the ASO molecule; or (vii) combinations thereof.
11. The ASRO of any one of claims 1 to 10, wherein the 5' wing (A'), the 3' wing (C'), or both comprise at least one methylsulfonylphosphoramidate (yp) internucleotide linkage.
12. The ASO molecule according to any one of claims 1 to 11, wherein the ASO molecule further comprises galactosamine.
13. The ASO molecule according to claim 12, wherein the galactosamine is N-acetylgalactosamine (GalNAc) of formula (VI): in m is 1, 2, 3, 4 or 5; Each n is independently 1 or 2; p is 0 or 1; Each R is independently H; Each Y is independently selected from -OP(=O)(SH)-, -OP(=O)(O)-, -OP(=O)(OH)- and -O- P(S)S-; Z is H or a second protecting group; L is a linker or L and Y in combination are a linker; and A is H, OH, a third protecting group, an activating group or an oligonucleotide.
14. The ASO molecule according to claim 12, wherein the galactosamine is N-acetylgalactosamine (GalNAc) of formula (VII): Where R z is OH or SH; and each n is independently 1 or 2.
15. The ASO molecule according to any one of claims 1 to 14, wherein; (i) the target RNA sequence is a viral gene; (ii) the target RNA sequence is a gene from a DNA virus; (iii) the target RNA sequence is a gene from a double-stranded DNA (dsDNA) virus; (iv) the target RNA sequence is a gene from a hepadnavirus; (v) the target RNA sequence is a gene from hepatitis B virus (HBV); (vi) the target RNA sequence is a gene from any one of genotypes AJ of HBV; or (vii) The target RNA sequence is selected from the S gene or X gene of HBV.
16. The ASO molecule according to any one of claims 1 to 14, wherein the target RNA sequence is selected from a gene encoding a methylation-controlled J protein (MCJ protein), a gene encoding TAZ, a gene encoding angiopoietin-like 3 (ANGPTL3), a gene encoding diacylglycerol acyltransferase 2 (DGAT2), and a gene encoding hydroxysteroid 17-β dehydrogenase 13 (HSD17B13).
17. The ASO molecule of any one of claims 1 to 16, wherein (i) the 5' wing of the ASO comprises 2 to 6 phosphorothioate-linked locked nucleosides, (ii) the 3' wing of the ASO comprises 2 to 6 phosphorothioate-linked locked nucleosides, or (iii) a combination thereof.
18. The ASO according to claim 17, wherein the locked nucleoside is selected from LNA, ScpBNA, AmNA, AmNA(N-Me), GuNA, GuNA(NR 11 ), where R 11 Selected from Me, Et, i-Pr, t-Bu and combinations thereof.
19. The ASO molecule according to any one of claims 1 to 18, wherein the central region of the ASO comprises at least 5 consecutive phosphorothioate-linked DNA nucleotides, at least 5 consecutive methylsulfonylphosphoramidate-linked DNA nucleotides, or at least 5 consecutive DNA nucleotides linked by one or more phosphorothioate internucleoside bonds and one or more methylsulfonylphosphoramidate internucleoside bonds.
20. The ASO molecule according to any one of claims 5 to 19, wherein the central region of the ASO comprises 8 to 10 consecutive phosphorothioate-linked DNA nucleotides, 8 to 10 consecutive methylsulfonylphosphoramidate-linked DNA nucleotides, or 8 to 10 DNA nucleotides linked by one or more phosphorothioate internucleoside bonds and one or more methylsulfonylphosphoramidate internucleoside bonds.
21. The ASO according to any one of claims 1 to 20, wherein the ASO comprises at least one modified nucleotide having the following structure: in: R is halogen or R'-C≡C-; and R' is C 6-12 Aryl, 5- to 12-membered heteroaryl, hydroxy-C 1-6 Alkyl or C 1-7 Alkanoyloxy.
22. The ASO according to any one of claims 1 to 21, wherein the ASO comprises at least one modified nucleotide having the following structure: in: W is independently O, N or S; R1, R2 and R5 are independently H or D; R3 is H or F; R4 is F or OCH3; and Base is in: R is halogen or R'-C≡C-; and R' for C 6-12 Aryl, 5- to 12-membered heteroaryl, hydroxyl C 1-6 Alkyl or C 1-7 Alkanoyloxy.
23. An ASO molecule as shown in Table 1.
24. A pharmaceutical composition comprising the ASO molecule according to any one of claims 1 to 23; and a pharmaceutically acceptable excipient.
25. The pharmaceutical composition of claim 24, further comprising 2, 3, 4, 5, 6, 7, 8, 9, 10 or more ASO molecules according to any one of claims 3 to 22.
26. The pharmaceutical composition of claim 24 or 25, further comprising an additional therapeutic agent.
27. The pharmaceutical composition of claim 26, wherein the additional therapeutic agent is selected from nucleotide analogs, nucleoside analogs, capsid assembly modulators (CAMs), recombinant interferons, entry inhibitors, small molecule immunomodulators, and oligonucleotide therapies, wherein the oligonucleotide therapies are optionally selected from additional antisense oligonucleotides (ASOs), short interfering nucleic acids (siNAs), NAPs, or STOPS TM .
28. A method of treating a subject suffering from hepatitis B virus (HBV) infection, the method comprising administering to the subject suffering from HBV an ASO according to any one of claims 1 to 23 or a pharmaceutical composition according to any one of claims 24 to 27.
29. The method of claim 28, further comprising administering an additional therapeutic agent.
30. The method of claim 29, wherein the additional therapeutic agent is selected from nucleotide analogs, nucleoside analogs, capsid assembly modulators (CAMs), recombinant interferons, entry inhibitors, small molecule immunomodulators, and oligonucleotide therapies, wherein the oligonucleotide therapies are optionally selected from additional antisense oligonucleotides (ASOs), short interfering nucleic acids (siNAs), NAPs, or STOPS TM .
31. The method of claim 28, wherein the additional therapeutic agent is selected from the group consisting of: ALG-010133, ALG-000184, recombinant interferon α2b, IFN-a, PEG-IFN-a-2a, lamivudine, telbivudine, adefovir dipivoxil, clavudine, entecavir, tenofovir alafenamide, tenofovir disoproxil, NVR3-778, BAY41-4109, JNJ-632, JN J-3989(ARO-HBV), RG6004, GSK3228836, REP-2139, REP-2165, AB-729, VIR-2218, DCR-HBVS, JNJ-6 379, GLS4, ABI-HO731, JNJ-440, NZ-4, RG7907, EDP-514, AB-423, AB-506, ABI-H03733 and ABI-H2158.
32. The method of any one of claims 28 to 31, wherein the ASO and the additional therapeutic agent are administered simultaneously or sequentially.
33. The method of any one of claims 28 to 32, wherein the treatment comprises reducing the viral load of HBV in the subject, reducing the level of viral antigens in the subject, or a combination thereof.
34. A method of reducing the expression of a target gene in a subject, the method comprising administering to the subject an ASO according to any one of claims 1 to 23 or a pharmaceutical composition according to any one of claims 24 to 27.
35. The method of claim 34, wherein the target gene is a gene endogenous to the subject or the target gene is not endogenous to the subject.
36. The method of claim 34 or 35, wherein the subject has a disease selected from hepatitis B virus (HBV), coronavirus infection, and liver disease, wherein the liver disease is optionally selected from non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and hepatocellular carcinoma (HCC).
37. The method according to any one of claims 28 to 36, wherein the subject is a mammal, optionally an adult.
38. The method of any one of claims 28 to 37, wherein the ASO is administered at a dose of at least 1 mg / kg, 2 mg / kg, 3 mg / kg, 4 mg / kg, 5 mg / kg, 6 mg / kg, 7 mg / kg, 8 mg / kg, 9 mg / kg, 10 mg / kg, 11 mg / kg, 12 mg / kg, 13 mg / kg, 14 mg / kg, or 15 mg / kg.
39. The method of any one of claims 28 to 38, wherein the ASO is present at 0.5 mg / kg to 50 mg / kg, 0.5 mg / kg to 40 mg / kg, 0.5 mg / kg to 30 mg / kg, 1 mg / kg to 50 mg / kg, 1 mg / kg to 40 mg / kg, 1 mg / kg to 30 mg / kg, 1 mg / kg to 20 mg / kg, 3 mg / kg to 50 mg / kg, 3 mg / kg to 40 mg / kg, 3 mg / kg to 30 mg / kg, 3 mg / kg to 20 mg / kg, 3 mg / kg to The invention can be administered at a dose of between 15 mg / kg, 3 mg / kg to 10 mg / kg, 4 mg / kg to 50 mg / kg, 4 mg / kg to 40 mg / kg, 4 mg / kg to 30 mg / kg, 4 mg / kg to 20 mg / kg, 4 mg / kg to 15 mg / kg, 4 mg / kg to 10 mg / kg, 5 mg / kg to 50 mg / kg, 5 mg / kg to 40 mg / kg, 5 mg / kg to 30 mg / kg, 5 mg / kg to 20 mg / kg, 5 mg / kg to 15 mg / kg, or 5 mg / kg to 10 mg / kg.
40. The method of any one of claims 28 to 39, wherein the ASO is administered at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 times.
41. The method of any one of claims 28 to 40, wherein the ASO is administered at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 times a day, at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 times a week, or at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 times a month.
42. The method of any one of claims 28 to 41, wherein the ASO is administered at least once every 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or 21 days.
43. The method of any one of claims 28 to 42, wherein the ASO is administered for a period of at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or 21 days, or at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 51, 52, 53, 54, or 55 weeks.
